

## PRIOR AUTHORIZATION CRITERIA

This list is current as of December 1, 2018 and pertains to the following formularies:

|  |               |
|--|---------------|
| 2018 Pharmacy Benefit Dimensions PDP Part D Formulary<br>Provided by Plumbers' and Pipefitters' Welfare Educational Fund | Version<br>18 |
|--|---------------|

Pharmacy Benefit Dimensions requires you (or your physician) to get prior authorization for certain drugs listed on the formularies above. This means that you will need to get approval from us before you fill your prescriptions. If you do not get approval, we may not cover the drug. These drugs are listed with a "PA" in the Requirements/Notes column on the formularies. This document contains the Prior Authorization requirements that are associated with the formularies listed above.

If you have any questions, please contact our Medicare Member Services Department at 1-800-665-1502 or, for TTY users 1-800-432-1110, October 1<sup>st</sup> – February 14<sup>th</sup>: Monday through Sunday from 8 a.m. to 8 p.m., February 15<sup>th</sup> – September 30<sup>th</sup>: Monday through Friday from 8 a.m. to 8 p.m.

Pharmacy Benefit Dimensions is a subsidiary of Independent Health. Independent Health is a PDP plan with a Medicare contract. Enrollment in Pharmacy Benefit Dimensions PDP depends on contract renewal between Independent Health and CMS.

The formulary may change at any time. You will receive notice when necessary.

# Abaloparatide (Tylmos)

## Products Affected

- TYMLOS

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.   |
| Exclusion Criteria           | Males  |
| Required Medical Information | Diagnosis of covered use. Documentation of the following may be requested: baseline serum calcium has been obtained and will be monitored throughout therapy, postmenopausal status, and documentation that at least one bisphosphonate has failed (or are contraindicated) and has value that assesses fracture risk (i.e. DEXA scan or prior fracture) |
| Age Restrictions             |  |
| Prescriber Restrictions      |  |
| Coverage Duration            | Two Years  |
| Other Criteria               | Because of the unknown relevance of the rodent osteosarcoma findings to humans, monitored use of abaloparatide for more than 2 years during a patient's lifetime is not recommended.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Abilify MyCite (aripiprazole tablets with sensor)

---

### Products Affected

- ABILIFY MYCITE ORAL TABLET 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Dementia-related psychosis  |
| <b>Required Medical Information</b> | Diagnosis of covered use, documentation of previous aripiprazole use (see Other Criteria).  |
| <b>Age Restrictions</b>             | 18 years of age or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | 1 year  |
| <b>Other Criteria</b>               | PA applies to new starts only. For approval, the patient must have documentation of at least a one-month trial of generic aripiprazole solution, tablets, or orally-disintegrating tablets. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ACTHAR HP

## Products Affected

- HP ACTHAR

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Acthar gel requested for IV administration, treatment of patients under 2 years of age in whom congenital infections are suspected, patients diagnosed with scleroderma, osteoporosis, systemic fungal infections, ocular herpes simplex, patients with a history of recent surgery, patients with a history of the presence of a peptic ulcer, congestive heart failure (CHF), uncontrolled hypertension, primary adrenocortical insufficiency, adrenocortical hyperfunction, sensitivity to proteins of porcine origin |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient height and weight if medication is requested for the treatment of infantile spasms, submission of blood pressure reading and baseline serum sodium and potassium levels  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Adagen

## Products Affected

- ADAGEN

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Medication is being requested as preparatory or support therapy for bone marrow transplantation, severe thrombocytopenia   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of plasma ADA activity and red blood cell dATP level and confirmation these laboratory values are scheduled to be obtained in accordance with the prescribing information, submission of body weight, submission of platelet count  |
| <b>Age Restrictions</b>             | Adagen is not approved for the treatment of adult patients   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | Remainder of the contract year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or clinic for administration, if the medication is being self-administered documentation is provided that the enrollee has been fully trained on how to prepare the injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## ADCIRCA

---

### Products Affected

- ADCIRCA
- *tadalafil (pah)*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D |
| <b>Exclusion Criteria</b>           | diagnosis of severe (Child Pugh Class C) hepatic impairment           |
| <b>Required Medical Information</b> | Diagnosis of covered use, patient weight and serum creatinine         |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | Limited to Pulmonology/ Cardiology                                    |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ADEMPAS

## Products Affected

- ADEMPAS

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Pregnancy, concurrent use with nitrates or nitric oxide donors in any form, concurrent use with phosphodiesterase (PDE) inhibitors  |
| <b>Required Medical Information</b> | Diagnosis of covered use, negative pregnancy test result for female patients of childbearing age, submission of documentation that female patient of childbearing age will have monthly pregnancy tests while on therapy and the month following therapy discontinuation, submission of patient weight and serum creatinine (to calculate creatinine clearance) |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to pulmonologists and cardiologists   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Adrucil (fluorouracil)

### Products Affected

- ADRUCIL INTRAVENOUS SOLUTION 500 MG/10ML
- *fluorouracil intravenous solution 2.5 gm/50ml, 5 gm/100ml*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Patients in a poor nutritional state, those with depressed bone marrow function, and those with potentially serious infections, or known hypersensitivity to fluorouracil  |
| <b>Required Medical Information</b> | Diagnosis of covered medical use and submission of baseline CBC (including WBC with differential), and submission of patient's weight for purposes of dosage verification  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology and Oncology   |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office for administration, if the medication is being self-administered documentation is provided that the enrollee has been fully trained on how to prepare the injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. PA Applies to New Starts. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# AFINITOR

## Products Affected

- AFINITOR
- AFINITOR DISPERZ

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use and if prescribed for the treatment of renal cell carcinoma, documented prior use of sunitinib or sorafenib, if prescribed for the treatment of postmenopausal women with advanced hormone receptor positive, human epidermal growth factor receptor 2 (HER-2) negative breast cancer documentation that Afinitor is being used in combination with exemestane after failure with letrozole or anastrozole therapy |
| <b>Age Restrictions</b>             | 1 YO or older   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## AIMOVIG (erenumab-aooe)

### Products Affected

- AIMOVIG
- AIMOVIG 140 DOSE

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of migraine days per month from medical chart, documentation patient has tried and failed or has a contraindication to at least two preferred alternatives such as propranolol, timolol, topiramate, and valproic acid. |
| <b>Age Restrictions</b>             | 18 years of age or older   |
| <b>Prescriber Restrictions</b>      | Restricted to neurology  |
| <b>Coverage Duration</b>            | Initially 3 months, then 1 year  |
| <b>Other Criteria</b>               | PA applies to all. Continuation requires documentation of clinically relevant response to therapy.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# AKYNZEO

## Products Affected

- AKYNZEO ORAL

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation patient will receive concurrent dexamethasone therapy as indicated based on level of chemotherapy regimen emetogenicity   |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | If Akynzeo is being administered related to cancer treatment and is a full replacement for intravenous administration of antiemetic therapy within 48 hours of cancer treatment, it is covered as a Part B benefit. Otherwise it is covered as a Part D benefit. In order to eligible for Part B coverage, the prescribing physician must indicate on the prescription that Akynzeo is being used as a full therapeutic replacement for an intravenous anti-emetic drug as part of a cancer chemotherapeutic regimen. If Akynzeo is dispensed for use after the 48-hour period, or if prescribed for conditions other than treatment of the effects of cancer treatment, it may be covered as a Part D benefit. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ALDARA

## Products Affected

- *imiquimod external*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of Covered Use   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | Physicians who specialize in the treatment of medical conditions most commonly treated with this medication are exempt from prior authorization including dermatologists, OB-GYN, colorectal surgeons and oncologists. |
| <b>Coverage Duration</b>            | Actinic keratosis, Genital and perianal warts- 16 weeks Superficial basal cell carcinoma- 6 weeks  |
| <b>Other Criteria</b>               | PA applies to new starts only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ALECENSA

## Products Affected

- ALECENSA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC), documentation that patient has progressed on or has a documented intolerance to crizotinib, submission of baseline ALT, AST, bilirubin, and CPK levels and confirmation that all will be monitored every 2 weeks during the first 2 months of therapy, then periodically during treatment, confirmation heart rate and blood pressure will be monitored regularly, Documentation that females of reproductive potential have been advised to use highly effective contraception during treatment and for 1 week following the final dose and that males have been advised to use highly effective contraception during treatment and for 3 months following the final dose |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Oncology and Hematology  |
| <b>Coverage Duration</b>            | 3 months initially, then annually thereafter  |
| <b>Other Criteria</b>               | Submission of liver function tests and CPK and documented response to treatment are required for continuation of approval. PA Applies to New Starts Only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ALGLUCOSIDASE

## Products Affected

- LUMIZYME

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of Covered Use   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office for administration, if the medication is being self-administered by the enrollee documentation is provided that the member has been fully trained on how to prepare the medication for injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Aliqopa (copanlisib)

### Products Affected

- ALIQOPA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Patients on strong CYP3A inducers such as carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort.  |
| <b>Required Medical Information</b> | Diagnosis of covered use AND documentation that baseline CBC tests and blood glucose levels have been obtained and will be monitored per package labeling AND documentation that patient has optimal blood pressure control and that the provider will monitor BP before and after infusions of copanlisib AND patient will be monitored for signs/symptoms of infections/cutaneous reactions while on therapy AND IF female of reproductive potential, a negative pregnancy test will be obtained prior to initiation AND that the patient will be counseled to use effective contraception during treatment with copanlisib and for at least 1 month after the last dose OR IF male, the patient has been counseled to use effective contraception during treatment and for at least one month after the last dose of copanlisib. |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology/Oncology  |
| <b>Coverage Duration</b>            | One year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details   |
|-----------------------|--|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown-bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration, if the medication is being administered in the enrollee's home, there are no associated safety concerns with preparation and/or administration of the medication documented in the prescribing information and if the medication is being administered in the enrollee's home by a route other than orally or subcutaneously, documentation is provided that the member has been fully trained on how to administer the medication safely and effectively if applicable. If these conditions are not satisfied these medications may be covered under Part B in accordance with the corresponding NCD/LCD if applicable.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



## ALUNBRIG (brigatinib)

---

### Products Affected

- ALUNBRIG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use-anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to crizotinib |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# AMPYRA

## Products Affected

- AMPYRA
- *dalfampridine er*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | History of seizure disorder, moderate or severe renal impairment (CrCl less than or equal to 50ml/min)   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use and Lab values including serum creatinine and patient weight, objective measurement of walking speed  |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to neurology   |
| <b>Coverage Duration</b>            | Three months, then every year  |
| <b>Other Criteria</b>               | Continuation of therapy requests require that the patient has demonstrated an improvement in walking speed from baseline measure (or maintenance of improvement if patient has been on long term therapy) or other objective measure of walking ability since starting Ampyra.PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Anadrol-50

## Products Affected

- ANADROL-50

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Carcinoma of the prostate or breast in male patients.Carcinoma of the breast in females with hypercalcemia- androgenic anabolic steroids may stimulate osteolytic resorption of bones. Oxymetholone can cause fetal harm when administered to pregnant women. It is contraindicated in women who are or may become pregnant. If the patient becomes pregnant while taking the drug, she should be apprised of the potential hazard to the fetus.Nephrosis or the nephrotic phase of nephritis. Hypersensitivity to the drug. Severe hepatic dysfunction |
| <b>Required Medical Information</b> | Diagnosis of covered use and submission of CBC and liver function tests   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | 6 months  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Antifungal

## Products Affected

- *itraconazole oral*
- SPORANOX ORAL SOLUTION

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D                                 |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use, fungal culture result identifying causative organism or positive KOH result |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | Infectious Disease are exempt from prior authorization.PA applies to all.                             |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ARCALYST

## Products Affected

- ARCALYST

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D            |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of Covered Use, TB skin test result obtained within the past 12 months |
| Age Restrictions             | 12 YO or older   |
| Prescriber Restrictions      |  |
| Coverage Duration            | One year   |
| Other Criteria               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Avelumab

## Products Affected

- BAVENCIO

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, documentation that provider is monitoring patient for immune-modulated pneumonitis, hepatitis, colitis, endocrinopathy, and nephritis as indicated in labeling and will reduce dose and/or discontinue as warranted, AND that the provider will premedicate the patient or alter the infusion rate as clinically indicated to minimize infusion complications.  |
| <b>Age Restrictions</b>             | 12 YO and older for Merkle Cell Carcinoma, 18 YO and older for other diagnoses  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology and Oncology  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or clinic for administration, if the medication is being self-administered documentation is provided that the enrollee has been fully trained on how to prepare the injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# BELEODAQ

## Products Affected

- BELEODAQ

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission of baseline CBC including ANC, RBC and platelet count, submission of baseline serum chemistry tests including renal (BUN and serum creatinine) and hepatic (bilirubin, AST and ALT) functions, confirmation CBC will be monitored weekly while on therapy and that serum chemistry tests including renal and hepatic functions will be obtained prior to the start of the first dose of each cycle, submission of patient's height and current weight to calculate BSA to confirm dosage, confirmation of the presence or absence of the UGT1A1*28 allele                              |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | limited to hematology and oncology  |
| <b>Coverage Duration</b>            | 1 year  |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: The provider administering the medication agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office for administration. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable or this clinical criteria. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# BENLYSTA

## Products Affected

- BENLYSTA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient current weight, confirmation the patient will be premedicated for prophylaxis against infusion reactions and hypersensitivity reactions if clinically indicated and the medication is being administered by healthcare providers prepared to properly prepare the infusion and manage hypersensitivity reactions, including anaphylaxis. |
| <b>Age Restrictions</b>             | 18yo or older  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration, if the medication is being administered in the enrollee's home, documentation is provided that the home care services provider has been fully trained on how to prepare the infusion and to administer the medication safely and effectively and is prepared to manage anaphylaxis. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable or this clinical criteria. The efficacy of BENLYSTA has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. BENLYSTA has not been studied in combination with other biologics or intravenous cyclophosphamide. Use of BENLYSTA is not recommended in these situations and therefore not authorized. PA applies to new starts.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# BENZNIDAZOLE

## Products Affected

- BENZNIDAZOLE

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D. |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of Chagas disease  |
| Age Restrictions             | Pediatrics age 2 to 12yo   |
| Prescriber Restrictions      | Infectious Disease   |
| Coverage Duration            | 60 days  |
| Other Criteria               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# BERINERT

## Products Affected

- BERINERT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | History of life-threatening immediate hypersensitivity reactions, including anaphylaxis, to C1 esterase inhibitor preparations  |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission of documentation that epinephrine will be immediately available in the event of an acute severe hypersensitivity reaction, and submission of patient's current weight for the purposes of dosage verification.   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | This medication may be covered as a Part D benefit if the patient is self-administering the medication and documentation is submitted stating that the patient has been provided instruction and training for self-administration outside of a clinic setting by their healthcare provider or if the provider is administering the medication in the office or infusion center and it is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: The physician/health care provider agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. This medication may be covered under Part B if obtained and administered by a physician incident to a physician service if the clinical criteria is met. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Bevyxxa (betrixaban)

---

### Products Affected

- BEVYXXA

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D. |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use   |
| Age Restrictions             |  |
| Prescriber Restrictions      |  |
| Coverage Duration            | Up to 42 days  |
| Other Criteria               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Bisphosphonate injection

## Products Affected

- *pamidronate disodium intravenous solution* • ZOMETA
- RECLAST
- *zoledronic acid intravenous concentrate*
- *zoledronic acid intravenous solution*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | If requested for zoledronic acid 0.05 mg/ml creatinine clearance less than 35ml/min, for all formulations -pregnancy  |
| <b>Required Medical Information</b> | Diagnosis of covered use for all products and for zoledronic acid 0.05 mg/ml - submission of patient weight and serum creatinine level, submission of serum calcium level, submission of serum alkaline phosphatase level for treatment of Paget's disease. For Zometa- submission of serum calcium level, For pamidronate-submission of serum calcium, magnesium, potassium, creatinine, Hgb and HCT levels, submission of serum alkaline phosphatase level for Paget's disease, |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | one year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy or furnished directly to the patient, it may be covered under Part D provided the following conditions are satisfied: A healthcare professional is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office, infusion center or homecare provider for administration. If these conditions are not satisfied this medication may be covered under Part B. Zoledronic acid 5mg/100ml and Recalst 5mg/100ml may be covered under Part B, for women with osteoporosis who meet the criteria for the Medicare home health benefit and have a bone fracture that a doctor certifies was related to post-menopausal osteoporosis. A doctor must certify that the woman is unable to learn how to or unable to give herself the drug by injection. PA applies to all.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Boniva injection

## Products Affected

- BONIVA INTRAVENOUS
- *ibandronate sodium intravenous solution 3 mg/3ml*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Patients with severe renal impairment (serum creatinine greater than 2.3mg/dL or creatinine clearance less than 30 mL/min), requests for self-administration of this medication, uncorrected hypocalcemia  |
| <b>Required Medical Information</b> | Medication is being administered for one of the following indications- treatment of osteoporosis in postmenopausal women or bone metastases in patients with prostate cancer, confirmation of osteoporosis diagnosis either through densitometry (T-score less than or equal to -2.5 at the total hip, femoral neck or lumbar spine) or clinically (documented presence of fragility fracture), submission of patient weight and serum creatinine level, submission of serum calcium level, submission of documentation stating why the IV formulation of Boniva is being given as opposed to the oral form of the drug which demonstrates one of the following- patient has a diagnosis of esophageal stricture, achalasia, or other severe esophageal dysmotility disorder or patient has a history of severe malabsorption making the use of oral bisphosphonates ineffective or patient has the inability to stand or sit upright for 60 minutes or patient has documented adverse effects following the initiation of treatment with the oral form of the medication that required the discontinuation of the oral form of the medication |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | one year   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy or furnished directly to the patient, it may be covered under Part D provided the following conditions are satisfied: A healthcare professional is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office, infusion center or homecare provider for administration. If these conditions are not satisfied this medication may be covered under Part B. This medication may be covered under Part B, for women with osteoporosis who meet the criteria for the Medicare home health benefit and have a bone fracture that a doctor certifies was related to post-menopausal osteoporosis. A doctor must certify that the woman is unable to learn how to or unable to give herself the drug by injection. PA applies to all.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# Bosulif

## Products Affected

- BOSULIF

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D  |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use, documentation of resistance or intolerance to at least one of the following prior therapies: imatinib, dasatinib, or nilotinib |
| Age Restrictions             | 18 YO or older   |
| Prescriber Restrictions      | Limited to oncologist/hematologist   |
| Coverage Duration            | One Year   |
| Other Criteria               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Botulinum Toxins

## Products Affected

- BOTOX
- DYSPORT
- XEOMIN

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.   |
| Exclusion Criteria           | Cosmetic purposes  |
| Required Medical Information | Diagnosis of covered use which will be proven with patient progress notes, documentation of labs and other diagnostic procedures supporting diagnosis along with documentation of any previously tried and failed therapies. |
| Age Restrictions             |  |
| Prescriber Restrictions      |  |
| Coverage Duration            | One year   |
| Other Criteria               | Requests for non-FDA approved indications will be evaluated according to CMS guidance on off-label requirements.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## BRAFTOVI/MEKTOVI (encorafenib/binimetinib)

### Products Affected

- BRAFTOVI
- MEKTOVI

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.  |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use, submission of FDA-approved test confirming presence of BRAF V600E or V600K mutation, serum potassium, and serum magnesium, confirmation that encorafenib and binimetinib will be co-administered. |
| Age Restrictions             | 18 years of age or older  |
| Prescriber Restrictions      | Restricted to hematology and oncology   |
| Coverage Duration            | 1 year  |
| Other Criteria               | PA applies to new starts only.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Briviact

## Products Affected

- BRIVIACT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Hypersensitivity to brivaracetam or any of the inactive ingredients   |
| <b>Required Medical Information</b> | Diagnosis of covered use, and documentation that patient will be monitored for the emergence of suicidal behavior and ideation, neurological adverse reactions including somnolence and fatigue and psychiatric adverse reactions including psychotic symptoms, irritability, depression, aggressive behavior and anxiety |
| <b>Age Restrictions</b>             | 16 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Neurologists   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA Applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Butalbital Containing products

### Products Affected

- *ascomp-codeine*
- BUPAP ORAL TABLET 50-300 MG
- *butalbital-acetaminophen oral tablet 50-325 mg*
- *butalbital-apap-caff-cod*
- *butalbital-apap-caffeine oral capsule*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*
- *butalbital-asa-caff-codeine*
- *butalbital-aspirin-caffeine oral capsule*
- ESGIC ORAL TABLET
- FIORICET ORAL CAPSULE
- FIORICET/CODEINE ORAL CAPSULE 50-300-40-30 MG
- FIORINAL
- FIORINAL/CODEINE #3
- *phrenilin forte oral capsule 50-300-40 mg*
- TENCON ORAL TABLET 50-325 MG
- VANATOL LQ
- ZEBUTAL ORAL CAPSULE 50-325-40 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Patient must have current diagnosis of headache or other medically accepted indication, and patient must have tried and failed, or have a contraindication to a preferred alternative, such as ibuprofen or acetaminophen or rizatriptan and documentation is submitted confirming that the provider is aware the medication is considered a high risk medication for elderly patients according to the Centers for Medicare and Medicaid services and documentation is provided which justifies the benefit of the identified drug and how that benefit outweighs the potential risks to the patient. |
| <b>Age Restrictions</b>             | PA required for 65 YO and older. No PA needed for less than age 65.  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CABOMETYX

---

## Products Affected

- CABOMETYX

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.  |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered medical use, submission of baseline blood pressure and documentation that blood pressure will be monitored periodically while on therapy, submission of documentation that females of reproductive potential have been advised to use effective contraception during treatment and for four months after the final dose is administered. |
| Age Restrictions             | 18 YO or older  |
| Prescriber Restrictions      | limited to Hematology or Oncology   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA Applies to New Starts Only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Calquence (acalabrutinib)

### Products Affected

- CALQUENCE

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Patients on proton pump inhibitors  |
| <b>Required Medical Information</b> | Diagnosis of covered use. Documentation that baseline CBC with differential is on file and will be monitored periodically as indicated by package labeling. Also, documentation that screening for second primary malignancies is being done and that the patient has been counseled to use protection from sun exposure. |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to hematology/oncology  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CARBAGLU

---

## Products Affected

- CARBAGLU

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D  |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use and lab values including plasma ammonia level |
| Age Restrictions             |  |
| Prescriber Restrictions      |  |
| Coverage Duration            | One Year   |
| Other Criteria               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# CERDELGA

## Products Affected

- CERDELGA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Patients who are CYP2D6 extensive metabolizers (EMs) and intermediate metabolizers (IMs) taking a strong CYP2D6 inhibitor with a strong or moderate CYP3A inhibitor, CYP2D6 IMs and PMs (poor metabolizers) taking a strong CYP3A inhibitor |
| <b>Required Medical Information</b> | Diagnosis of covered use, CYP2D6 metabolizer status as detected by an FDA-cleared test for determining CYP2D6 genotype, submission of patient's current weight and serum creatinine level or eGFR, submission of baseline ECG               |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | one year  |
| <b>Other Criteria</b>               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CEREZYME

## Products Affected

- CEREZYME INTRAVENOUS SOLUTION  
RECONSTITUTED 400 UNIT

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient body weight,documentation that Gaucher disease results in one or more of the following conditions-anemia (HGB less than10 g/dL for females, Hgb less than 11 g/dL for males-submission of Hgb required), thrombocytopenia (platelet count less than 100,000/uL-submission of platelet count required),bone disease other than Erlenmeyer flask deformity or mild osteopenia or significant hepatomegaly or splenomegaly as evidenced by MRI or CT scan results showing that spleen is 5 times normal size or liver is 1.25 times normal size,documentation that the healthcare setting and providers are prepared to manage hypersensitivity reactions including anaphylaxis |
| <b>Age Restrictions</b>             | 2 YO and older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details   |
|-----------------------|--|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy or furnished directly to the patient, it may be covered under Part D provided the following conditions are satisfied:</p> <ul style="list-style-type: none"> <li>A health care provider is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office, infusion center or to the home care provider for administration</li> </ul> <p>If these conditions are not satisfied this medication may be covered under Part B. PA applies to new starts only.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CESAMET

## Products Affected

- CESAMET

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of documentation that patient has tried and failed to adequately respond to at least one conventional antiemetic therapy.   |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | If Cesamet is being administered related to cancer treatment and is a full replacement for intravenous administration of antiemetic therapy within 48 hours of cancer treatment, it is covered as a Part B benefit. Otherwise it is covered as a Part D benefit. In order to eligible for Part B coverage, the prescribing physician must indicate on the prescription that Cesamet is being used as a full therapeutic replacement for an intravenous anti-emetic drug as part of a cancer chemotherapeutic regimen. If Cesamet is dispensed for use after the 48-hour period, or if prescribed for conditions other than treatment of the effects of cancer treatment, it may be covered as a Part D benefit |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CHENODAL

---

## Products Affected

- CHENODAL

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D  |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use, patient weight, submission of the following laboratory values: AST, ALT, serum cholesterol |
| Age Restrictions             | 18 YO or older   |
| Prescriber Restrictions      |  |
| Coverage Duration            | 24 months  |
| Other Criteria               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CHOLBAM

## Products Affected

- CHOLBAM

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission of baseline liver function tests including AST, ALT, GGT, alkaline phosphatase, bilirubin and INR, submission of patient weight for the purpose of dosage verification |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Chorionic gonadotropin

## Products Affected

- *chorionic gonadotropin intramuscular*
- *novarel*
- *pregnyl*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically accepted indications not otherwise excluded from Part D |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CINQAIR

## Products Affected

- CINQAIR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | History of hypersensitivity to reslizumab or excipients in the formulation  |
| <b>Required Medical Information</b> | Diagnosis of covered use of treatment of severe asthma in patients with eosinophilic phenotype, submission of pulmonary function test results including FEV1, submission of blood eosinophil count documenting 150 cells/mcL obtained within 6 weeks prior to therapy initiation or 300 cells/mcL within 12 months of therapy initiation, submission of documentation that patient's symptoms are poorly controlled with inhaled corticosteroids, frequency of inhaled short-acting beta2-agonist therapy, submission of frequency of daily and nighttime symptoms and exacerbations, effect of exacerbations on activity. Confirmation that the patient will receive treatment in the doctor's office or clinic and be observed for an appropriate amount of time after each treatment, documentation that the healthcare setting and providers are prepared to manage life-threatening anaphylaxis. |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Allergy and Pulmonology  |
| <b>Coverage Duration</b>            | One Year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | Continuation of therapy requests require objective documentation from the prescriber that the patient's symptoms have improved. The medication may be covered under Part D provided the following conditions are satisfied: A physician is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or clinic for administration. If these conditions are not satisfied, the medication may be covered under Part B. PA Applies to All. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CINRYZE

## Products Affected

- CINRYZE

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically accepted indications not otherwise excluded by Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | diagnosis of covered use   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied:A physician/health care provider is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. This medication may be covered under Part B if administered by a physician incident to a physician service.PA applies to new starts only. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Cometriq

## Products Affected

- COMETRIQ (100 MG DAILY DOSE)
- COMETRIQ (140 MG DAILY DOSE)
- COMETRIQ (60 MG DAILY DOSE)

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, baseline blood pressure reading, baseline laboratory values including urine protein values, serum bilirubin level, AST, ALT , documentation that patient will be monitored for symptoms of GI perforation and fistulas, documnetation that patient does not have recent history of hemorrhage or hemoptysis, baseline oral examination results and confirmation oral exams will be performed periodically during therapy |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to oncology or hematology  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to new starts only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CORLANOR

## Products Affected

- CORLANOR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Acute decompensated heart failure, Blood pressure less than 90/50 mmHg, Sick sinus syndrome, sinoatrial block or 3rd degree AV block- unless a functioning demand pacemaker is present, Resting heart rate less than 60 bpm prior to treatment, Severe hepatic impairment, Pacemaker dependence (heart rate maintained exclusively by the pacemaker)  |
| <b>Required Medical Information</b> | Diagnosis of covered use described as is indicated to reduce the risk of hospitalization for worsening heart failure in patients with stable, symptomatic chronic heart failure with left ventricular ejection fraction less than or equal to 35%, who are in sinus rhythm with resting heart rate greater than or equal to 70 beats per minute and either are on maximally tolerated doses of beta-blockers or have a contraindication to beta-blocker use, submission of current baseline blood pressure reading, confirmation that patient does not have any of the following: Acute decompensated heart failure, Sick sinus syndrome, sinoatrial block or 3rd degree AV block- unless a functioning demand pacemaker is present, Resting heart rate less than 60 bpm prior to treatment, Severe hepatic impairment or Pacemaker dependence (heart rate maintained exclusively by the pacemaker) |
| <b>Age Restrictions</b>             | 18yo or older   |
| <b>Prescriber Restrictions</b>      | Requested by or under the documented recommendation of a cardiologist   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# COTELLIC

## Products Affected

- COTELLIC

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission of FDA-approved test confirming presence of BRAF V600E or V600K mutation, confirmation that Cotellic will be administered in combination with vemurafenib, documentation that patient will be monitored for new primary malignancies including cutaneous and non-cutaneous prior to initiation of therapy, and every 2 months while on therapy and for 6 months following the last dose of Cotellic, confirmation that LVEF has been evaluated prior to therapy initiation and that LVEF is scheduled to be re-assessed 1 month after therapy initiation and every 3 months thereafter while on therapy, documentation that ophthalmological evaluations will be performed at regular intervals during treatment, submission of baseline liver function tests to include AST and ALT, CPK, and creatinine levels, documentation that females of reproductive potential have been advised to use effective contraception during treatment and for 2 weeks following discontinuation |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Oncology or Hematology   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA Applies to New Starts Only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## crisaborole

---

### Products Affected

- EUCRISA

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D. |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use   |
| Age Restrictions             | 2 YO or older  |
| Prescriber Restrictions      | Limited to dermatology   |
| Coverage Duration            | Initial 30 days, re-authorization one year                             |
| Other Criteria               | Re-authorization requires a positive response to therapy.              |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CUPRIMINE

## Products Affected

- CUPRIMINE ORAL CAPSULE 250 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Except for the treatment of Wilson's disease or certain patients with cystinuria, use of penicillamine during pregnancy is contraindicated (see WARNINGS). Although breast milk studies have not been reported in animals or humans, mothers on therapy with penicillamine should not nurse their infants. Patients with a history of penicillamine-related aplastic anemia or agranulocytosis should not be restarted on penicillamine. Because of its potential for causing renal damage, penicillamine should not be administered to rheumatoid arthritis patients with a history or other evidence of renal insufficiency |
| <b>Required Medical Information</b> | Diagnosis of covered use and laboratory analysis applicable to indication for use.  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | PA applies to all.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CYRAMZA

## Products Affected

- CYRAMZA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, if used for treatment of advanced gastric or gastro-esophageal junction adenocarcinoma, documentation of disease progression on or after prior fluopyrimidine or platinum containing regimen, if for treatment of metastatic NSCLC with disease progression on or after platinum-based chemotherapy, if for the treatment of metastatic colorectal cancer, documentation of disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. Submission of documentation that the Patient will be pretreated with an IV H1 antagonist and if appropriate dexamethasone and APAP. Submission of baseline blood pressure, baseline urinary protein level, baseline thyroid function tests including TSH, patient weight and confirmation patient will be monitored while on therapy for the development of hemorrhage, arterial thromboembolic events, hypertension, GI perforations, impaired wound healing, proteinuria and thyroid dysfunction |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology/Oncology Prescribers  |
| <b>Coverage Duration</b>            | one year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician or health care provider is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office, infusion center or homecare provider for administration. If these conditions are not satisfied this medication may be covered under Part B in accordance with this criteria and/or an applicable NCD/LCD. PA for new starts only.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# CYSTARAN

---

## Products Affected

- CYSTARAN

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded by Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only.                                      |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Cytovene

## Products Affected

- CYTOVENE
- *ganciclovir sodium intravenous solution reconstituted*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Patients with documented hypersensitivity to ganciclovir or acyclovir.   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient weight and serum creatinine level, submission of CBC and platelet count, submission of documentation that the potential benefits outweigh the risks when prescribed for the treatment of patients less than 18 years of age  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | Remainder of the contract year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: A health care provider is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office, infusion center or to the home care provider for administration. If these conditions are not satisfied this medication may be covered under Part B. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# DARZALEX

## Products Affected

- DARZALEX

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient weight for the purposes of dosage calculation, documentation that the healthcare setting and provider are prepared to manage infusion reactions, including life-threatening anaphylaxis, documentation that women of reproductive potential have been advised to use effective contraception during treatment and for three months after cessation of therapy  |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Hematology or Oncology  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: A healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion reactions is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. If these conditions are not satisfied this medication may be covered under Part B. PA Applies to New Starts Only. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Deferasirox (Exjade/Jadenu)

### Products Affected

- EXJADE
- JADENU
- JADENU SPRINKLE

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, Current lab values including ferritin, CBC, LFTs, serum creatinine, urine protein values, documentation that member has had yearly ophthalmic and auditory testing          |
| <b>Age Restrictions</b>             | 2 YO or older   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | Three months  |
| <b>Other Criteria</b>               | For continuation: Documentation of ferritin level within last 3 months and CBC, LFT, Serum Creatinine, Urine Protein Value, ophthalmic and auditory testing have been performed within the last year. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Deflazacort

## Products Affected

- *emflaza*

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.         |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use and treatment failure (or intolerance) of prednisone. |
| Age Restrictions             | 5 YO and older   |
| Prescriber Restrictions      |  |
| Coverage Duration            | 1 year   |
| Other Criteria               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Denosumab

## Products Affected

- PROLIA
- XGEVA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Hypocalcemia, pregnancy, documented hypersensitivity to denosumab  |
| <b>Required Medical Information</b> | Prolia is being requested for one of the following indications-treatment of postmenopausal women with confirmed diagnosis of osteoporosis at high risk for fracture, treatment to increase bone mass in men with osteoporosis at high risk for fracture, treatment to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer, treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer, confirmation of osteoporosis diagnosis either through densitometry (T-score less than or equal to -2.5 at the total hip, femoral neck or lumbar spine) or clinically (documented presence of fragility fracture), high risk for fracture is defined as a history of osteoporotic fracture or multiple risk factors for fracture or patients who have failed or are intolerant of other available osteoporosis therapy, submission of serum calcium level. |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | Remainder of the contract year   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy or furnished directly to the patient, it may be covered under Part D provided the following conditions are satisfied: A healthcare professional is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office, infusion center or homecare provider for administration. If these conditions are not satisfied this medication may be covered under Part B. PA applies to all.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



## DIFICID

---

### Products Affected

- DIFICID

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use  |
| Age Restrictions             | 18 YO or older  |
| Prescriber Restrictions      |   |
| Coverage Duration            | One course of therapy (10 days)                                       |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Digoxin

## Products Affected

- *digitek oral tablet 250 mcg*
- *digox oral tablet 250 mcg*
- *digoxin injection*
- *digoxin oral solution*
- *digoxin oral tablet 250 mcg*
- LANOXIN INJECTION SOLUTION 0.25 MG/ML
- LANOXIN ORAL TABLET 187.5 MCG, 250 MCG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Patient must have a current diagnosis of atrial fibrillation or congestive heart failure, patient must have tried and failed to respond adequately to 0.125mg of digoxin and submission of patient's current CrCl (ml per min)(or current weight and serum creatinine level is submitted for the purposes of calculating CrCL)and result is greater than or equal to 30ml per min |
| <b>Age Restrictions</b>             | PA applies to all patients 65 YO or older   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | Prior authorization is not required for doses less than or equal to 0.125mg per day. PA applies to all patients 65 YO or older.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## DOPTELET (avatrombopag)

---

### Products Affected

- DOPTELET

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D. |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use.  |
| <b>Age Restrictions</b>             | 18 years of age or older   |
| <b>Prescriber Restrictions</b>      | Restricted to gastroenterology, hematology, and surgery                |
| <b>Coverage Duration</b>            | 5 days   |
| <b>Other Criteria</b>               | PA applies to all.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# DUOPA

## Products Affected

- DUOPA ENTERAL

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | DUOPA is contraindicated in patients taking nonselective monoamine oxidase (MAO) inhibitors  |
| <b>Required Medical Information</b> | Diagnosis of covered use and confirmation patient has a naso-jejunal tube for short-term administration or a PEG-J for long-term administration. |
| <b>Age Restrictions</b>             | 18yo or older  |
| <b>Prescriber Restrictions</b>      | Limited to Neurology prescribers   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | PA applies to all.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Dupilumab

## Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION  
 PREFILLED SYRINGE 300 MG/2ML

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use. Documentation of treatment with at least a moderate strength topical corticosteroid for at four weeks or have a contraindication to their use or therapy is not otherwise advisable.  |
| <b>Age Restrictions</b>             | 18 YO and older   |
| <b>Prescriber Restrictions</b>      | Restricted to dermatology   |
| <b>Coverage Duration</b>            | 16 weeks then up to one year  |
| <b>Other Criteria</b>               | For continuation, a positive clinical response must be documented. Upon starting this medication, the continuation period will be granted for only 36 additional weeks if no response was seen at 16 weeks OR if a positive clinical response is seen at 16 weeks approval will be granted for one year. A non-positive clinical response at 52 weeks from the initiation of therapy will be deemed a treatment failure. If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office for administration, if the medication is being self-administered documentation is provided that the enrollee has been fully trained on how to prepare the injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Durvalumab (Imflinzi)

## Products Affected

- IMFINZI

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use. Documentation of that the following baseline laboratory measurements are available and will be monitored throughout use: liver function tests, TSH, HbA1C, platelet count, serum creatinine/eGFR. If a female of reproductive potential, documentation that patient has been counseled to use effective contraception during treatment and for at least 3 months after the last dose of medication.   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | Limited to Hematology/Oncology  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or clinic for administration, if the medication is being self-administered documentation is provided that the enrollee has been fully trained on how to prepare the injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# EGRIFTA

## Products Affected

- EGRIFTA SUBCUTANEOUS SOLUTION  
RECONSTITUTED 1 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Pregnancy  |
| <b>Required Medical Information</b> | Diagnosis of covered use, patient weight, patient waist circumference  |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | Continuation of therapy requests require confirmation that the patient has demonstrated a clinical improvement (or maintenance of improvement once achieved) from baseline. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Elderly High Risk

### Products Affected

- *benztropine mesylate oral*
- BUTISOL SODIUM ORAL TABLET 30 MG
- *carisoprodol oral*
- *chlorpropamide*
- *cyproheptadine hcl oral*
- *dipyridamole oral*
- *disopyramide phosphate oral*
- *guanfacine hcl er*
- *guanfacine hcl oral*
- INDOCIN ORAL
- *indomethacin er*
- *indomethacin oral*
- INTUNIV
- *ketorolac tromethamine oral*
- *meprobamate*
- *methyldopa oral*
- *nifedipine oral*
- NORPACE
- NORPACE CR
- *phenadoz rectal suppository 12.5 mg*
- PHENERGAN INJECTION
- *phenobarbital oral elixir*
- *phenobarbital oral tablet*
- PREFEST
- SPRIX
- TALWIN
- *thioridazine hcl oral*
- *trihexyphenidyl hcl*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | All three of the following criteria are met: 1) Diagnosis of covered use, 2) documentation that provider is aware medication is considered a high risk medication for elderly patients according to the Centers for Medicare and Medicaid services, and 3) documentation that the benefits of the identified drug outweigh the potential risks to the patient. |
| <b>Age Restrictions</b>             | PA applies to patients 65 YO and older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# EMPLICITI

## Products Affected

- EMLICITI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation Empliciti will be used in combination with lenalidomide and dexamethasone and that patient has received one to three prior multiple myeloma therapies, submission of patient weight for the purposes of dose verification, confirmation that the patient will be premedicated for prophylaxis against infusion reactions and hypersensitivity reactions, and the medication is being administered by healthcare providers prepared to properly prepare the infusion and manage hypersensitivity reactions, including anaphylaxis, submission of baseline liver function tests (AST, ALT, total bilirubin and alkaline phosphatase)and confirmation that liver enzymes will be monitored periodically while on therapy |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Hematology or Oncology  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy or furnished directly to the patient, it may be covered under Part D provided the following conditions are satisfied: A healthcare professional is administering the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office, infusion center or homecare provider for administration. If these conditions are not satisfied this medication may be covered under Part B. PA Applies to New Starts Only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# EMSAM

---

## Products Affected

- EMSAM

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Enasidenib (Idhifa)

## Products Affected

- IDHIFA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use. Documentation of testing for isocitrate dehydrogenase-2 mutation, prior therapies tried and failed, baseline laboratory tests are available such as of CBC, LFTs, serum creatinine, calcium, potassium and phosphorus levels and confirmation these labs will be monitored periodically throughout therapy as indicated per package labeling. Also, documentation that the patient has been counseled about the risks and signs of differentiation syndrome and that therapy will be stopped if signs or symptoms of this occur and that the benefits of treatment outweigh any potential risks. |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Restricted to Hematology or Oncology   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | Females of reproductive potential and males with partners of reproductive potential must be counseled that effective contraception should be used throughout therapy and for one month after the last dose of enasidenib.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## EPCLUSA (sofosbuvir/velpatasvir)

### Products Affected

- EPCLUSA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | EPCLUSA and ribavirin combination regimen is contraindicated in patients for whom ribavirin is contraindicated  |
| <b>Required Medical Information</b> | Diagnosis of covered use and laboratory confirmation of hepatitis C virus (HCV) genotype 1a, 1b, 2, 3, 4, 5, or 6 infection, submission of baseline HCV RNA level, documentation of whether cirrhosis is present or not and whether or not it is compensated (Child-Pugh A) or decompensated (Child-Pugh B and C), submission of eGFR as the safety and efficacy of Epclusa has not been established in patients with eGFR less than 30ml/min/1.73 m <sup>2</sup> ), confirmation that patients with decompensated cirrhosis will receive concomitant ribavirin therapy unless ribavirin therapy is otherwise clinically not indicated, submission of patient current weight for patients with decompensated cirrhosis for the purposes of verifying ribavirin dosage (recommended dose is 1000mg per day for patients less than 75kg and 1200mg for those weighing at least 75 kg) |
| <b>Age Restrictions</b>             | 18 YO and older   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | 12 weeks  |
| <b>Other Criteria</b>               | PA applies to all.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## EPIDIOLEX (cannabidiol)

---

### Products Affected

- EPIDIOLEX

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D. |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use.  |
| <b>Age Restrictions</b>             | 2 years of age or older  |
| <b>Prescriber Restrictions</b>      | Restricted to neurology  |
| <b>Coverage Duration</b>            | 1 year   |
| <b>Other Criteria</b>               | PA applies to new starts only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# EPOGEN

## Products Affected

- EPOGEN INJECTION SOLUTION 3000 UNIT/ML, 4000 UNIT/ML

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D   |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use. Lab values from bloodwork indicating hemoglobin and iron levels. Blood pressure is also required. |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | 3 Months  |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ERIVEDGE

---

## Products Affected

- ERIVEDGE

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, pregnancy status for female patients        |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to oncology or dermatology                                    |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## ERLEADA (apalutamide)

---

### Products Affected

- ERLEADA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D. |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use.  |
| <b>Age Restrictions</b>             | 18 years of age or older   |
| <b>Prescriber Restrictions</b>      | Restricted to hematology and oncology.                                 |
| <b>Coverage Duration</b>            | 1 year   |
| <b>Other Criteria</b>               | PA applies to new starts only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# ERWINAZE

## Products Affected

- ERWINAZE INJECTION

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Erwinaze is contraindicated if patients have a history of serious hypersensitivity reactions including anaphylaxis to Erwinaze, and/or a history of serious pancreatitis, serious thrombosis, or serious hemorrhagic events with prior L-asparaginase therapy   |
| <b>Required Medical Information</b> | Diagnosis of covered use including confirmation that patient has developed hypersensitivity to E. coli-derived asparaginase, submission of patient height and current weight, submission of baseline blood glucose level and confirmation blood glucose levels will be monitored periodically during treatment, confirmation that this medication is being administered in a setting with the proper resuscitation equipment and other agents necessary (epinephrine, oxygen, intravenous steroids, antihistamines etc) to treat anaphylaxis available  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | Limited to oncology and hematology  |
| <b>Coverage Duration</b>            | one year  |
| <b>Other Criteria</b>               | If the medication is being obtained at a participating pharmacy, it may be covered under Part D provided the following conditions are satisfied: The physician agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. PA applies to new starts only. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Erythropoietins

## Products Affected

- ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 300 MCG/ML, 40 MCG/ML, 60 MCG/ML
- ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE
- EPOGEN INJECTION SOLUTION 10000 UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML
- PROCRIT
- RETACRIT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use. Lab values from bloodwork indicating hemoglobin or hematocrit AND serum iron AND total iron-binding capacity (TIBC) AND transferrin tests. All lab values must be within 30 days of request date. Documentation that the patient does not have uncontrolled hypertension. |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | For non-ESRD related conditions: 90 days, For ESRD related conditions: 1 year   |
| <b>Other Criteria</b>               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## ESBRIET/OFEV

### Products Affected

- ESBRIET
- OFEV

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of baseline AST, ALT, and bilirubin, confirmation liver function tests will be monitored monthly for the first 3 months after therapy initiation with Ofev and then at least every 3 months thereafter while on therapy, confirmation that liver function tests will be monitored monthly for the the first 6 months after therapy initiation with Esbriet and every 3 months thereafter while on therapy, |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | one year  |
| <b>Other Criteria</b>               | For Ofev-prescriber documents that the benefits outweigh the potential risks for patients with known bleeding or gastrointestinal perforation risk. For Esbriet-submission of patient's current weight and serum creatinine level for the purposes of calculating creatinine clearance and if the patient is receiving dialysis treatments. PA applies to all.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Estrogens

## Products Affected

- ACTIVELLA
- ALORA
- *amabelz*
- ANGELIQ
- CLIMARA PRO
- COMBIPATCH
- DIVIGEL TRANSDERMAL GEL 0.5 MG/0.5GM, 1 MG/GM
- DUAVEE
- ELESTRIN
- ESTRACE ORAL
- *estradiol oral*
- *estradiol transdermal*
- *estradiol-norethindrone acet*
- *estropipate oral tablet 0.75 mg, 1.5 mg*
- EVAMIST
- *fyavolv*
- JINTELI
- *lopreeza*
- MENEST ORAL TABLET 0.3 MG, 0.625 MG, 1.25 MG
- MENOSTAR
- *mimvey*
- *mimvey lo*
- MINIVELLE
- *norethindrone-eth estradiol*
- PREMARIN ORAL
- PREMPHASE
- PREMPRO
- VIVELLE-DOT

| PA Criteria        | Criteria Details   |
|--------------------|--|
| Covered Uses       | All medically accepted indications not otherwise excluded from Part D. |
| Exclusion Criteria |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Required Medical Information</b> | Submission of documentation that the drug requested is being prescribed for an FDA approved indication for that specific drug and documentation that the provider is aware of the associated risks of systemic estrogen products in elderly women including an increased risk of breast and endometrial cancer with prolonged use and an increased risk of clot formation without cardioprotective effect, confirmation that the prescriber is aware the medication is considered high risk for elderly patients by the Centers for Medicare and Medicaid services and submission of justification by the prescriber which explains the benefits of the requested drug and how that benefit outweighs the potential risks for the specific patient, confirmation that a taper and therapy discontinuation has been attempted after every two years of therapy and documentation of a trial and failure or contraindication to two preferred alternatives for each established indication. With the exception of the treatment of the vasomotor symptoms of menopause for which there are no preferred alternatives but still requires all other criteria listed above, the preferred alternatives include: Vulvar or vaginal atrophy: Estrace cream, Premarin cream, Osteoporosis: alendronate, ibandronate, raloxifene. |
| <b>Age Restrictions</b>             | PA require for 65 YO and older. No PA needed for less than age 65.   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Fabrazyme

## Products Affected

- FABRAZYME

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Fabrazyme requested for self-administration in the home setting   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient weight, documentation that provider and healthcare setting is prepared to manage life-threatening infusion reactions, documentation that patients with compromised cardiac function will be closely monitored during drug administration  |
| <b>Age Restrictions</b>             | 8 YO and older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: A physician is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office for administration. If these conditions are not satisfied this medication may be covered under Part B. PA applies to new starts |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# FARYDAK

## Products Affected

- FARYDAK

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically-accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, documentation that the patient has received at least 2 prior regimens (including bortezomib and an immunomodulatory agent), submission of baseline CBC documenting platelet count is at least $100 \times 10^9/L$ and absolute neutrophil count is at least $1.5 \times 10^9/L$ and confirmation CBC will be monitored at least weekly during treatment, submission of baseline ECG documenting QTcF is less than 450 msec prior to initiation of Farydak therapy, submission of baseline serum electrolytes (including potassium and magnesium), submission of baseline liver function tests (including AST, ALT, and total bilirubin) |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Restricted to Hematology/Oncology   |
| <b>Coverage Duration</b>            | 8 cycles initially, an additional 8 cycles if clinical benefit seen   |
| <b>Other Criteria</b>               | Farydak therapy is not authorized for patients with a history of recent myocardial infarction, unstable angina or patients with active infections. For patients with mild hepatic impairment the maximum starting dose authorized is 15mg. For patients with moderate hepatic impairment or those patients receiving concurrent strong CYP3A inhibitor therapy, the maximum starting dose authorized is 10mg.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Fasenra (benralizumab)

### Products Affected

- FASENRA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use of treatment of severe asthma in patients with eosinophilic phenotype, submission of pulmonary function test results including FEV1, submission of laboratory confirmation of eosinophilic asthma diagnosis (serum eosinophil count, sputum eosinophil count or lung biopsy), submission of documentation that patient's symptoms are poorly controlled with inhaled corticosteroids, frequency of inhaled short-acting beta2-agonist therapy, submission of frequency of daily and nighttime symptoms and exacerbations, effect of exacerbations on activity. Confirmation that the patient will receive treatment in the doctor's office or clinic and be observed for an appropriate amount of time after each treatment, documentation that the healthcare setting and providers are prepared to manage life-threatening anaphylaxis. |
| <b>Age Restrictions</b>             | 12 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Allergy, Pulmonology, or Immunology   |
| <b>Coverage Duration</b>            | One year   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



| PA Criteria           | Criteria Details   |
|-----------------------|--|
| <b>Other Criteria</b> | Continuation of therapy requests requires objective documentation from the prescriber that the patient's symptoms have improved. The medication may be covered under Part D provided the following conditions are satisfied: A physician is administering the medication and he/she agrees to accept brown-bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or clinic for administration. If these conditions are not satisfied, the medication may be covered under Part B. PA Applies to All. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Fentanyl transmucosal

## Products Affected

- ABSTRAL
- *fentanyl citrate buccal*
- FENTORA BUCCAL TABLET 100 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- LAZANDA
- SUBSYS

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Treatment of opioid non-tolerant patients, treatment of acute or postoperative pain including headache, migraines or dental pain  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of documentation that patient who is already receiving and is tolerant to opioid therapy requires fentanyl transmucosal for the management of their underlying, persistent cancer pain |
| <b>Age Restrictions</b>             | 18 years or older (buccal film, buccal tablet, sublingual tablet, sublingual spray, intranasal spray) or 16 years or older (lozenge, lollipop)  |
| <b>Prescriber Restrictions</b>      | Oncology prescribers are exempt for prior authorization   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to all except when prescribed by oncology.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# FERRIPROX

## Products Affected

- FERRIPROX

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D  |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use, lab values including serum ferritin levels, CBC, ANC, platelet count, serum ALT, plasma zinc level |
| Age Restrictions             |  |
| Prescriber Restrictions      |  |
| Coverage Duration            | One Year   |
| Other Criteria               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# FIRAZYR

---

## Products Affected

- FIRAZYR

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use  |
| Age Restrictions             | 18 YO or older  |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# FIRMAGON

## Products Affected

- FIRMAGON

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Firmagon should not be administered to anyone with a previous hypersensitivity reaction to degarelix, or to pregnant women.  |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission of baseline prostate-specific antigen (PSA) and serum testosterone level, submission of baseline ECG and serum electrolyte levels   |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Hematology/Oncology Prescribers   |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | Continuation of therapy requests require submission of updated PSA, serum electrolyte testosterone levels. If this medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If the physician administering the medication agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or clinic for administration, if the medication is being self-administered documentation is provided that the enrollee has been fully trained on how to properly prepare the injection and to administer the medication safely and effectively. If these conditions are not satisfied this medication may be covered under Part B. PA applies to new starts only. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# FLECTOR

## Products Affected

- FLECTOR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Flector Patch is contraindicated in patients with a known hypersensitivity to diclofenac. Flector Patch is contraindicated in patients who have experienced asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Flector Patch is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery. Flector Patch is contraindicated for use on non-intact or damaged skin resulting from any etiology, including exudative dermatitis, eczema, infection lesions, burns or wounds |
| <b>Required Medical Information</b> | Diagnosis of covered use which includes the topical treatment of acute pain due to minor strains, sprains, and contusions.  |
| <b>Age Restrictions</b>             | 18 YO or Older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | Three months  |
| <b>Other Criteria</b>               | Approval is only provided for three months of therapy as Flector is only indicated for the treatment of acute pain due to minor strains, sprains and contusions. Acute pain is defined as short-term pain not lasting longer than a three month period. PA applies to all.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# FORTEO

## Products Affected

- FORTEO SUBCUTANEOUS SOLUTION 600 MCG/2.4ML

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, postmenopausal, Lab values (serum calcium level), documentation that other treatment options have failed (or are contraindicated) and has value that assesses fracture risk.   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | 2 Years  |
| <b>Other Criteria</b>               | This medication may be covered under Part B, for women with osteoporosis who meet the criteria for the Medicare home health benefit and have a bone fracture that a doctor certifies was related to post-menopausal osteoporosis. A doctor must certify that the woman is unable to learn how to or unable to give herself the drug by injection. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## GALAFOLD (migalastat)

### Products Affected

- GALAFOLD

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Severe renal impairment (eGFR less than 30 mL/min/1.73 m <sup>2</sup> ) or end stage renal disease requiring dialysis  |
| <b>Required Medical Information</b> | Diagnosis of covered use. Documentation that the patient has an amenable galactosidase alpha gene variant (see section 12.1, table 2 of package insert for full list) based on in vitro assay data as interpreted by a clinical genetics professional. |
| <b>Age Restrictions</b>             | 18 years of age or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | 1 year   |
| <b>Other Criteria</b>               | PA applies to new starts only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# GATTEX

## Products Affected

- GATTEX

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of documentation that a colonoscopy (or alternate imaging) of the entire colon with polyp removal was performed within 6 months prior to starting treatment and is scheduled to be performed at the end of year 1 of Gattex therapy, submission of baseline laboratory values including bilirubin, alkaline phosphatase, lipase and amylase obtained within 6 months prior to starting Gattex therapy and confirmation these laboratory assessments are scheduled to be performed every 6 months while on therapy, submission of serum creatinine and patient weight for the purposes of creatinine clearance calculation and dose verification |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# GILOTRIF

## Products Affected

- GILOTRIF

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use. Documentation that females of reproductive potential have been advised to use highly effective contraception during Gilotrif therapy and for at least two weeks after therapy discontinuation, documentation that patient will have periodic liver function monitoring while on therapy |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | limited to oncology or hematology   |
| <b>Coverage Duration</b>            | one year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# GLEEVEC

## Products Affected

- GLEEVEC
- *imatinib mesylate*

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use  |
| Age Restrictions             |   |
| Prescriber Restrictions      | Limited to Oncologists or Hematologists                               |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Gocovri (amantidine ER)

---

### Products Affected

- GOCOVRI
- OSMOLEX ER

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D. |
| Exclusion Criteria           | Patients with end stage renal disease                                  |
| Required Medical Information | Diagnosis of covered use   |
| Age Restrictions             | 18 YO or older   |
| Prescriber Restrictions      | Limited to neurology   |
| Coverage Duration            | One year   |
| Other Criteria               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Grastek

## Products Affected

- GRASTEK

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Severe, unstable or uncontrolled asthma, history of any severe systemic allergic reaction, history of any severe local reaction to sublingual allergen immunotherapy, history of eosinophilic esophagitis, hypersensitivity to gelatin, mannitol and sodium hydroxide   |
| <b>Required Medical Information</b> | Grastek is being requested for the treatment of grass pollen induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens, therapy is being initiated at least 12 weeks before the expected onset of each grass pollen season, confirmation that the first dose of medication will be administered in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases and that the patient will be observed for at least 30 minutes after administration of the first dose to monitor for signs and symptoms of a severe systemic or severe local allergic reaction. |
| <b>Age Restrictions</b>             | Patients 5 through 65 years of age  |
| <b>Prescriber Restrictions</b>      | Limited to Allergy or Immunology Prescribers  |
| <b>Coverage Duration</b>            | one year  |
| <b>Other Criteria</b>               | Confirmation auto-injectable epinephrine therapy has been prescribed and patient has been instructed on the proper use of emergency self-injection epinephrine.PA applies to all.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Growth Hormone

## Products Affected

- GENOTROPIN
- GENOTROPIN MINIQUICK
- HUMATROPE
- NORDITROPIN FLEXPRO
- NUTROPIN AQ NUSPIN 10
- NUTROPIN AQ NUSPIN 20
- NUTROPIN AQ NUSPIN 5
- OMNITROPE
- SAIZEN
- SAIZEN CLICK.EASY
- SAIZENPREP
- ZOMACTON

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, growth failure documentation, IGF 1 levels, bone age if applicable based on patient age and diagnosis,height, weight, creatinine clearance, fasting glucose, lipid profile, DEXA scan  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | Limited to Endocrinologist and Nephrologist.   |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | Requests for continuation of therapy require annual submission of updated IGF 1 levels, bone age if applicable based on patient age and diagnosis, height, weight, creatinine clearance and at least one of the following for the treatment of adult patients: fasting glucose, lipid profile or DEXA scan. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Haegarda (C1 esterase inhibitor)

---

### Products Affected

- HAEGARDA

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D. |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use   |
| Age Restrictions             |  |
| Prescriber Restrictions      |  |
| Coverage Duration            | one year   |
| Other Criteria               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# HARVONI

## Products Affected

- HARVONI

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use and laboratory confirmation of hepatitis C virus (HCV) genotype 1a, 1b, 4, 5, and 6 infection, submission of baseline HCV RNA level, documentation of patient's CHC treatment status as either treatment-naïve or treatment-experienced and whether cirrhosis is present or not, submission of eGFR  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | 12 or 24 weeks of therapy depending on treatment status and presence of cirrhosis   |
| <b>Other Criteria</b>               | For treatment-naïve patients with cirrhosis or treatment-naïve or treatment-experienced without cirrhosis approval is for 12 weeks of therapy. For treatment-naïve patients without cirrhosis who have pre-treatment HCV RNA less than 6 million IU/mL, 8 weeks of therapy may be considered by the provider. For treatment-experienced patients with cirrhosis approval is for 24 weeks of therapy. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# Hemangeol

## Products Affected

- HEMANGEOL

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | asthma or history of bronchospasm, premature infant with corrected age less than 5 weeks, infants weighing less than 2 kg, bradycardia (less than 80 beats per minute), greater than first degree heart block, decompensated heart failure, blood pressure less than 50/30mmHg, pheochromocytoma, known hypersensitivity to propranolol |
| <b>Required Medical Information</b> | Diagnosis of covered use, Infant is at least 5 weeks corrected age or older, submission of current weight (must be at least 2 kg), treatment is being initiated at ages 5 weeks to 5 months   |
| <b>Age Restrictions</b>             | Minimum patient age of 5 weeks up to 1 year of age  |
| <b>Prescriber Restrictions</b>      | limited to pediatric otolarangologist or ENT specialist or pediatric ophthalmologist  |
| <b>Coverage Duration</b>            | 6 months  |
| <b>Other Criteria</b>               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# HETLIOZ

---

## Products Affected

- HETLIOZ

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           | None  |
| Required Medical Information | Diagnosis of covered use  |
| Age Restrictions             | 18 YO or older  |
| Prescriber Restrictions      | limited to sleep specialists and neurologists                         |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# HYDROXYZINE

## Products Affected

- *hydroxyzine hcl oral tablet*
- *hydroxyzine pamoate oral*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | hypersensitivity to cetirizine or levocetirizine   |
| <b>Required Medical Information</b> | 1. Patient must have a diagnosis of: Anxiety or Pruritus AND 2. For treatment of pruritus patient must have tried and had an inadequate response to a second generation antihistamine such as levocetirizine or desloratadine. AND 3. For treatment of anxiety, patient must have tried and failed or had an inadequate response to at least 2 other FDA-approved products for the management of anxiety. OR 4. for the treatment of sedation when used as premedication and following general anesthesia 5. Documentation is submitted confirming that the provider is aware the medication is considered a high risk medication for elderly patients according to the Centers for Medicare and Medicaid services AND 6. Justification is submitted which explains the benefits of the identified drug and how that benefit outweighs the potential risks to the patient. |
| <b>Age Restrictions</b>             | Applies to 65 years of age and older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# IBRANCE

## Products Affected

- IBRANCE

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically-accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission confirming HER2-negative status, confirmation that the treatment regimen will include concomitant use of an aromatase inhibitor or fulvestrant, submission of baseline CBC. |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology/Oncology   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | PA applies to new starts only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ILARIS

## Products Affected

- ILARIS SUBCUTANEOUS SOLUTION

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use. TB skin test result obtained within past 12 months, submission of pediatric patient weight, submission of documentation that patient has received all recommended vaccinations as appropriate including pneumococcal vaccine and inactivated influenza vaccine prior to initiation of therapy . When requested for the treatment of CAPS-confirmed diagnosis of CAPS including genetic testing for variant FCAS or MWS, documentation patient is not receiving concomitant TNF inhibitor therapy. When requested for the treatment of SJIA-patient with confirmed diagnosis of active SJIA defined by the prominence of systemic and inflammatory features including spiking fevers, rash, swelling and inflammation of lymph nodes, liver and spleen, and high white blood cell and platelet counts, submission of CBC including platelet count. |
| <b>Age Restrictions</b>             | 2 YO and older  |
| <b>Prescriber Restrictions</b>      | when requested for SJIA limited to rheumatology   |
| <b>Coverage Duration</b>            | 1 year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: A physician/health care provider is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. This medication may be covered under Part B if administered by a physician incident to a physician service. Continuation of therapy requires submission of objective documentation of positive patient response or maintenance of response, Submission of updated TB skin test result obtained within the past 12 months. PA applies to all.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# IMBRUVICA

## Products Affected

- IMBRUVICA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of baseline CBC and confirmation that patient will have CBC checked monthly, submission of baseline serum creatinine level and confirmation that patient's serum creatinine levels will be monitored periodically while on therapy |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | limited to oncology and hematology  |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Immune Globulin

## Products Affected

- BIVIGAM 20 GM/400ML, 5 GM/100ML, 5 GM/50ML
- CARIMUNE NF INTRAVENOUS SOLUTION RECONSTITUTED 12 GM, 6 GM
- FLEBOGAMMA DIF
- GAMMAGARD
- GAMMAGARD S/D LESS IGA
- GAMMAKED
- GAMMAPLEX INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 20 GM/200ML, 20 GM/400ML, 5 GM/100ML, 5 GM/50ML
- GAMUNEX-C
- *octagam intravenous solution 1 gm/20ml*
- OCTAGAM INTRAVENOUS SOLUTION 10 GM/100ML, 10 GM/200ML, 2 GM/20ML, 2.5 GM/50ML, 20 GM/200ML, 25 GM/500ML, 5 GM/100ML, 5 GM/50ML
- PRIVIGEN

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use. Documentation of baseline laboratory analysis/diagnostic procedures to indicate the need for Immune Globulin therapy at initiation. Baseline labs must be within the last 30 days.  |
| <b>Age Restrictions</b>             | For HIV diagnosis ONLY: 13 YO or younger  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | Acute conditions/New starts: 3 months Renewal of Chronic Condition: 1 year  |
| <b>Other Criteria</b>               | Immune Globulin therapy is covered as a part B benefit if administered in the home for the treatment of primary immune deficiency. It is covered as a Part D benefit for all other indications when administered in the home. For all indications, if administered in the physician office or infusion center it is covered as a Part B benefit. For continuation of all diagnosis documentation of the clinical response to therapy must be submitted. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# INCRELEX/IPLEX

## Products Affected

- INCRELEX

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, documentation of primary IGFD or growth hormone gene deletion in patients who have developed neutralizing antibodies to growth hormone, IGF-1 level, growth hormone level |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | Limited to Endocrinologist.   |
| <b>Coverage Duration</b>            | 6 Months  |
| <b>Other Criteria</b>               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Ingrezza (valbenazine)

---

### Products Affected

- INGREZZA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>For the treatment of adults with tardive dyskinesia (TD) |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Injectable Oncology Drugs

---

## Products Affected

- ABRAXANE
- *adriamycin intravenous solution*
- ALIMTA
- ALKERAN INTRAVENOUS
- ARRANON
- ARZERRA INTRAVENOUS CONCENTRATE 100 MG/5ML
- AVASTIN
- *azacitidine*
- BICNU
- *bleomycin sulfate injection solution reconstituted 30 unit*
- *bortezomib*
- *busulfan*
- BUSULFEX
- CAMPTOSAR INTRAVENOUS SOLUTION 100 MG/5ML
- *cisplatin intravenous solution 100 mg/100ml, 50 mg/50ml*
- *cladribine intravenous solution 10 mg/10ml*
- *clofarabine*
- *cytarabine (pf) injection solution 100 mg/ml*
- *cytarabine injection solution*
- *dacarbazine intravenous solution reconstituted 200 mg*
- DACOGEN
- *dactinomycin*
- *daunorubicin hcl intravenous injectable*
- *daunorubicin hcl intravenous solution*
- *decitabine*
- *dexrazoxane intravenous solution reconstituted 250 mg*
- *docetaxel intravenous concentrate 80 mg/4ml*
- *docetaxel intravenous solution 160 mg/16ml, 80 mg/8ml*
- DOCETAXEL INTRAVENOUS SOLUTION 20 MG/2ML
- DOXIL
- *doxorubicin hcl intravenous solution*
- *doxorubicin hcl liposomal*
- ELITEK
- ELLENCE INTRAVENOUS SOLUTION 200 MG/100ML
- *epirubicin hcl intravenous solution 200 mg/100ml, 50 mg/25ml*
- ERBITUX
- FASLODEX INTRAMUSCULAR SOLUTION 250 MG/5ML
- *fludarabine phosphate intravenous solution reconstituted*
- FOLOTYN INTRAVENOUS SOLUTION 40 MG/2ML
- *gemcitabine hcl intravenous solution reconstituted 1 gm*
- GEMZAR INTRAVENOUS SOLUTION RECONSTITUTED 1 GM
- HALAVEN
- HERCEPTIN INTRAVENOUS SOLUTION RECONSTITUTED 150 MG, 440 MG
- IDAMYCIN PFS INTRAVENOUS SOLUTION 20 MG/20ML
- *idarubicin hcl intravenous solution 10 mg/10ml*
- IFEX INTRAVENOUS SOLUTION RECONSTITUTED 1 GM
- *ifosfamide intravenous solution reconstituted 1 gm*
- *irinotecan hcl intravenous solution 100 mg/5ml*
- ISTODAX (OVERFILL)
- IXEMPRA KIT INTRAVENOUS SOLUTION RECONSTITUTED 45 MG
- JEVTANA
- KADCYLA
- *melphalan hcl*

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

- *mesna*
- MESNEX INTRAVENOUS
- *mitomycin intravenous*
- *mitoxantrone hcl intravenous concentrate 25 mg/12.5ml*
- MUSTARGEN
- NIPENT
- ONCASPAR INJECTION
- *oxaliplatin*
- *paclitaxel intravenous concentrate 100 mg/16.7ml, 300 mg/50ml*
- PROLEUKIN
- SYNRIBO
- TAXOTERE INTRAVENOUS CONCENTRATE 80 MG/4ML
- *temsirolimus*
- TORISEL
- TREANDA INTRAVENOUS SOLUTION RECONSTITUTED
- TRELSTAR MIXJECT
- TRISENOX INTRAVENOUS SOLUTION 12 MG/6ML
- VELCADE INJECTION
- VIDAZA
- *vinblastine sulfate intravenous solution*
- *vincasar pfs*
- *vincristine sulfate intravenous*
- *vinorelbine tartrate intravenous solution 50 mg/5ml*
- VYXEOS
- YERVOY INTRAVENOUS SOLUTION 50 MG/10ML
- ZANOSAR
- ZINECARD INTRAVENOUS SOLUTION RECONSTITUTED 250 MG

| PA Criteria        | Criteria Details  |
|--------------------|---|
| Covered Uses       | All medically accepted indications not otherwise excluded by Part D |
| Exclusion Criteria |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Required Medical Information</b> | Diagnosis of covered FDA-labeled indication, submission of CBC including platelet count   |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | limited to hematology, oncology, or HIV specialist  |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration, if the medication is being administered in the enrollee's home, there are no associated safety concerns with preparation and/or administration of the medication documented in the prescribing information and if the medication is being administered in the enrollee's home by a route other than orally or subcutaneously, documentation is provided that the member has been fully trained on how to administer the medication safely and effectively if applicable. If these conditions are not satisfied these medications may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. PA applies to all.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Injectable Testosterone

## Products Affected

- DEPO-TESTOSTERONE INTRAMUSCULAR SOLUTION
- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml*
- *testosterone enanthate intramuscular solution*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically accepted indications not otherwise excluded from Part D                      |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, serum testosterone level, documentation that patient has been evaluated for the presence of prostate cancer prior to initiation of therapy |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | Urology and Endocrinology prescribers are exempt.  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to all except when written by Urology and Endocrinology prescribers.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# INLYTA

## Products Affected

- INLYTA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, documentation of one prior systemic therapy failure, submission of laboratory values including baseline ALT, AST, bilirubin, TSH, urine protein values, pregnancy status for female patients, submission of baseline blood pressure reading |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# INTRON-A

## Products Affected

- INTRON A

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | autoimmune hepatitis, decompensated liver disease  |
| <b>Required Medical Information</b> | Diagnosis of covered use, for all approved indications for use-submission of triglyceride levels, hemoglobin, complete and differential white blood cell counts, platelet count, serum electrolytes, ALT,serum bilirubin level, serum albumin level, TSH, for the treatment of malignant melanoma-submission of the date of surgical treatment,for the treatment of AIDS-Related Kaposi's Sarcoma-submission of total CD4 count,for the treatment of chronic hepatitis C- submission of the following laboratory values HCV RNA, prothrombin time, baseline serum creatinine level, laboratory confirmation of hepatitis C virus, documentation of previous response to therapy if applicable, for chronic Hepatitis B infection-documentation patient has been serum HBsAG positive for at least 6 months with evidence of HBV replication, submission of the following laboratory values Prothrombin time. |
| <b>Age Restrictions</b>             | 18 YO or older for the treatment of Hairy Cell Leukemia, malignant melanoma, follicular lymphoma,Condylomata Acuminata, AIDS-Related Kaposi's Sarcoma 3 YO or older for the treatment of Chronic Hepatitis C 1 YO or older for the treatment of Chronic Hepatitis B  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



| PA Criteria           | Criteria Details   |
|-----------------------|--|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration, if the medication is being administered in the enrollee's home, documentation is provided that the member has been fully trained on how to prepare the injection and to administer the medication safely and effectively. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. PA applies to new starts only.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# INVEGA TRINZA

## Products Affected

- INVEGA TRINZA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Known hypersensitivity to paliperidone, risperidone, or to any excipients in the formulation   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, documentation that the patient has been adequately treated with the 1-month paliperidone palmitate extended-release injectable suspension for at least four (4) months.  |
| <b>Age Restrictions</b>             | 18 YO and older  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: A physician/health care provider is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. If these conditions are not satisfied this medication may be covered under Part B. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# IRESSA

## Products Affected

- IRESSA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation of EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test, submission of baseline liver function tests (AST, ALT, bilirubin) and confirmation periodic liver function testing will be performed while on therapy, documentation that females of reproductive potential have been advised to use highly effective contraception during therapy and for at least two weeks following completion of therapy |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology or Oncology   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA Applies to New Starts Only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## IVIG

---

### Products Affected

- GAMASTAN S/D INTRAMUSCULAR  
INJECTABLE

| PA Criteria        | Criteria Details   |
|--------------------|--|
| Covered Uses       | All medically accepted indications not otherwise excluded from Part D  |
| Exclusion Criteria | IgA deficient patients with antibodies against IgA and a history of hypersensitivity, patients with a history of severe systemic reactions to human immunoglobulin |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Required Medical Information</b> | <p>IVIG is requested for one of the following conditions-Primary Immunodeficiency, Immune-mediated Thrombocytopenia (ITP), Kawasaki disease, Human Immunodeficiency Virus (HIV)(for pediatric use only), Bone marrow transplantation, Chronic B-cell lymphocytic leukemia (CLL) and for the following biopsy-proven conditions-Pemphigus vulgaris, Bullous pemphigoid, Mucous membrane pemphigoid, benign mucous membrane pemphigoid, with or without mention of ocular movement, Epidermolysis bullosa acquisita in patients who demonstrate rapidly progressive disease in which a clinical response could not be affected quickly enough using conventional agents. Primary humoral immunodeficiency is defined as severe impairment of antibody capacity with 1 of the following conditions: Congenital agammaglobulinemia, Common variable immunodeficiency, Wiskott-Aldrich syndrome, X-linked immunodeficiency with hyper-IgM, Severe combined immunodeficiencies, Deficient qualitative or quantitative antibody production, patients with at least 1 bacterial infection directly attributable to this deficiency. For ITP submission of platelet count, for CLL-IgG level of less than 600 mg/dl and Recent history of serious bacterial infection requiring either oral or IV antibiotic therapy, for HIV-Age younger than 14 years old and Evidence of qualitative or quantitative humoral immunologic defects and Current bacterial infections, despite appropriate antimicrobial prophylaxis, for CIDP-unequivocal CIDP diagnosis and patient has proved refractory to or intolerant of prednisone or azathioprine given in therapeutic doses over at least 3 months and patient has a Rankin Scale neurologic function assessment score of at least 3 at the time of initial therapy, for Dermatomyositis, Polymyositis-patient with severe active illness.</p> |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | remainder of the contract year   |
| <b>Other Criteria</b>               | <p>IVIG is covered as a part B benefit if administered in the home for the treatment of primary immune deficiency. It is covered as a Part D benefit for all other indications when administered in the home. For all indications if administered in the physician office or infusion center it is covered as a Part B benefit. PA applies to all.</p>   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Jakafi

## Products Affected

- JAKAFI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use and lab values including CBC, platelet count. Patient's creatinine clearance is required. |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to oncology or hematology  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Jublia/Kerydin

### Products Affected

- JUBLIA
- KERYDIN

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.  |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use, submission of culture proven Trichophyton rubrum or Trichophyton mentagrophytes infection, patient has tried and failed to respond to or tolerate oral terbinafine therapy or a documented contraindication to its use exists |
| Age Restrictions             | 18 YO or older  |
| Prescriber Restrictions      |   |
| Coverage Duration            | 48 weeks  |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# JUXTAPID

## Products Affected

- JUXTAPID

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Pregnancy or moderate or severe hepatic impairment (Child-Pugh Class B or C) or active liver disease.   |
| <b>Required Medical Information</b> | Diagnosis of covered use and lab values including baseline transaminase levels including: ALT, AST,alkaline phosphatase, total bilirubin, baseline LDL-C, total cholesterol (TC), apoB, non-HDL-C, documentation of negative pregnancy test result in females of reproductive potential, confirmed diagnosis of HoFH and renal indices, documentation of treatment failure with Repatha or contraindication to use. |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



## JYNARQUE (tolvaptan)

### Products Affected

- JYNARQUE

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | History of signs or symptoms of significant liver impairment or injury (not including uncomplicated polycystic liver disease), uncorrected abnormal blood sodium concentrations, inability to sense or respond to thirst, hypovolemia, uncorrect urinary outflow obstruction, anuria |
| <b>Required Medical Information</b> | Diagnosis of covered use.  |
| <b>Age Restrictions</b>             | 18 years of age or older   |
| <b>Prescriber Restrictions</b>      | Restricted to nephrology   |
| <b>Coverage Duration</b>            | 1 year   |
| <b>Other Criteria</b>               | PA applies to all.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# KALYDECO

---

## Products Affected

- KALYDECO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D                                  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, cystic fibrosis mutation test result, baseline ALT and AST laboratory values |
| <b>Age Restrictions</b>             | 2 YO or older  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Kanuma

## Products Affected

- KANUMA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient's current weight for the purposes of dosage calculation, documentation that the healthcare setting and providers are prepared to manage infusion reactions including anaphylaxis  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: A physician/health care provider is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. If these conditions are not satisfied this medication may be covered under Part B. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# KETOCONAZOLE

## Products Affected

- *ketoconazole oral*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Patients with acute or chronic liver disease, treatment of fungal meningitis or fungal infections of the skin or nails, patients receiving concomitant therapy with aplrazolam, midazolam, triazolam, cisapride, dofetilide, HMG-CoA reductase inhibitors, nisoldipine, pimozide, eplerenone, ergot alkaloids or quinidine   |
| <b>Required Medical Information</b> | Ketoconazole is being requested for the treatment of one of the following culture proven, systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis or paracoccidioidomycosis, submission of baseline ALT, AST, total bilirubin, alkaline phosphatase, prothrombin time and INR, confirmation patient's ALT will be monitored weekly for the duration of treatment, confirmation from the prescriber that the potential benefits of therapy outweigh the risks |
| <b>Age Restrictions</b>             | 2 YO or older  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | Six months   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# KEVEYIS

## Products Affected

- KEVEYIS

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Concomitant use of high dose aspirin, hypersensitivity to dichlorphenamide or other sulfonamides, severe pulmonary disease limiting compensation to metabolic acidosis, hepatic insufficiency   |
| <b>Required Medical Information</b> | Diagnosis of primary hyperkalemic periodic paralysis, primary hypokalemic period paralysis, or related variants, submission of baseline serum potassium and baseline serum bicarbonate and confirmation these lab values will be measured periodically while on therapy |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | Initially 2 months, then annually thereafter  |
| <b>Other Criteria</b>               | Documentation of patient's response to Keveyis at 2 months is required for continuation of approval. PA Applies to All.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# KEYTRUDA

## Products Affected

- KEYTRUDA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission of baseline AST and ALT, baseline serum creatinine, baseline thyroid function tests, documentation that appropriate dose adjustments will be made as needed and/or corticosteroid administration, in the event of immune-mediated adverse reactions, submission of patient's current weight.  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology and Oncology Prescribers   |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: The provider administering the medication agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable or this clinical criteria. PA applies to new starts only. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## KISQALI (ribociclib)

### Products Affected

- KISQALI 200 DOSE
- KISQALI 400 DOSE
- KISQALI 600 DOSE
- KISQALI FEMARA 200 DOSE
- KISQALI FEMARA 400 DOSE
- KISQALI FEMARA 600 DOSE

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.  |
| Exclusion Criteria           | Patients on rifampin, phenytoin, and carbamazepine  |
| Required Medical Information | Diagnosis of covered use and genetic tumor testing showing that the primary tumor type is HR Positive, HER-2 negative and attestation that patient has advanced or metastatic disease and will be taking concurrently with an aromatase inhibitor. The provider must also attest that baseline ECG, LFT's, CDC have been obtained and will be monitored per prescribing guidelines. |
| Age Restrictions             |   |
| Prescriber Restrictions      | Limited to oncology or hematology   |
| Coverage Duration            | One year  |
| Other Criteria               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# KORLYM

## Products Affected

- KORLYM

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | pregnancy, patients on concurrent long-term, life-saving corticosteroid therapy, patients on concurrent simvastatin, lovastatin, or CYP3A substrates with narrow therapeutic ranges, such as cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus, female patient with a history of unexplained vaginal bleeding, female patient with endometrial hyperplasia with atypia or endometrial carcinoma |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of baseline serum potassium level, submission of negative pregnancy test result in female patients of reproductive potential, submission of serum creatinine level and patient's weight (for creatinine clearance calculation and dose verification), submission of baseline AST, ALT and alkaline phosphatase   |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# KUVAN

## Products Affected

- KUVAN

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use, phenylalanine level, patient weight         |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | 6 months  |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# KYNAMRO

## Products Affected

- KYNAMRO SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Patients with moderate or severe hepatic impairment, or active liver disease, including unexplained persistent elevations of serum transamniases   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of the following baseline lab values ALT, AST, alkaline phosphatase, total bilirubin, LDL-C, apo B, TC, non-HDL-C, documentation patient is using Kynamro as an adjunct to lipid-lowering medications |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | six months   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Kyprolis (Carfilzomib)

### Products Affected

- KYPROLIS

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use including documentation of prior therapies consistent with NCCN guidelines and/or FDA approved indications, documentation that the following values will be monitored to ensure safe dosing of carfilzomib: Left Ventricular Ejection Fraction (LVEF), serum creatinine, serum uric acid level, blood pressure, platelet counts, liver enzymes (including AST, ALT, and Bilirubin), documentation that if any of the preceding values are elevated or uncontrolled that consideration to stopping therapy and/or dose reduction will be given. Documentation that thromboprophylaxis has been considered for patients at high risk of thrombosis while on carfilzomib. Documentation that provider is aware that inadequate hydration while using carfilzomib will increase the risk of tumor lysis syndrome/renal toxicity. |
| <b>Age Restrictions</b>             | 18 YO and older   |
| <b>Prescriber Restrictions</b>      | Limited to hematology and oncology providers  |
| <b>Coverage Duration</b>            | 1 year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details   |
|-----------------------|--|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office for administration. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. PA for New Starts Only.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# LARTRUVO (olaratumab)

## Products Affected

- LARTRUVO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D. LARTRUVO™ is a platelet-derived growth factor receptor alpha (PDGFR-a) blocking antibody indicated, in combination with doxorubicin, for the treatment of adult patients with soft tissue sarcoma (STS) with a histologic subtype for which an anthracycline-containing regimen is appropriate and which is not amenable to curative treatment with radiotherapy or surgery.  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation patient will receive concurrent doxorubicin therapy and patient is not a candidate for curative treatment with radiotherapy or surgery, submission of patient weight for purposes of dose verification, confirmation patient will be premedicated with diphenhydramine and dexamethasone and that Lartruvo will be administered by IV infusion only, confirmation female patients of reproductive potential have been advised of the potential risk to the fetus and to use effective contraception during treatment with Lartruvo and for 3 months after the last dose |
| <b>Age Restrictions</b>             | 18yo or older  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: The provider administering the medication agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable or this clinical criteria. PA applies to new starts only.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# LENVIMA

## Products Affected

- LENVIMA 10 MG DAILY DOSE
- LENVIMA 12 MG DAILY DOSE
- LENVIMA 14 MG DAILY DOSE
- LENVIMA 18 MG DAILY DOSE
- LENVIMA 20 MG DAILY DOSE
- LENVIMA 24 MG DAILY DOSE
- LENVIMA 4 MG DAILY DOSE
- LENVIMA 8 MG DAILY DOSE

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically-accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission of creatinine clearance or current body weight and serum creatinine level for the purposes of calculation of creatinine clearance by the Cockcroft-Gault equation, submission of baseline blood pressure showing blood pressure is controlled, confirmation patient will be monitored for clinical symptoms or signs of cardiac decompensation, submission of baseline ALT and AST, submission of baseline proteinuria evaluation via dipstick (at least less than 2 grams), submission of baseline serum calcium and TSH level, Documentation that blood pressure will be monitored after 1 week, then every 2 weeks for the first 2 months, and then at least monthly thereafter, documentation that liver function will be evaluated before initiation, then every 2 weeks for the first 2 months, and at least monthly thereafter, documentation that serum calcium will be monitored at least monthly, documentation that TSH will be monitored monthly |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology/Oncology  |
| <b>Coverage Duration</b>            | one year  |
| <b>Other Criteria</b>               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Letairis

## Products Affected

- LETAIRIS

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Pregnancy, idiopathic pulmonary fibrosis  |
| <b>Required Medical Information</b> | Diagnosis of covered use, negative pregnancy test result for female patients of childbearing age, submission of baseline AST, ALT and bilirubin levels, submission of baseline HGB level and confirmation HGB will be measured after 1 month of therapy and periodically thereafter |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Pulmonologists and Cardiologists   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# Leukine

## Products Affected

- LEUKINE INTRAVENOUS

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use, WBC count, ANC                              |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | 3 Months  |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Lidoderm (lidocaine transdermal)

### Products Affected

- *lidocaine external patch 5 %*
- LIDODERM

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | lidocaine transdermal is contraindicated in patients with a known history of sensitivity to local anesthetics of the amide type, or to any other component of the product. |
| <b>Required Medical Information</b> | Diagnosis of covered use   |
| <b>Age Restrictions</b>             | 18YO or older  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# LONSURF

## Products Affected

- LONSURF

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.   |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered medical use: metastatic colorectal cancer for patients who have been previously treated with fluoropyrimidine, oxaliplatin, and irinotecan based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy, submission of patient's height and current weight to calculate BSA to confirm dosage, submission of CBC prior to initiation of therapy and confirmation that it will be monitored on Day 15 of each cycle, documentation that women of reproductive potential have been advised to use effective contraception during treatment, documentation of patient's KRAS status |
| Age Restrictions             | 18 YO or older   |
| Prescriber Restrictions      | Limited to Hematology and Oncology   |
| Coverage Duration            | One Year   |
| Other Criteria               | PA Applies to New Starts Only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## LUCEMYRA (lofexidine)

---

### Products Affected

- LUCEMYRA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Congenital long QT syndrome, severe coronary insufficiency, recent myocardial infarction, cerebrovascular disease, chronic renal failure |
| <b>Required Medical Information</b> | Diagnosis of covered use.  |
| <b>Age Restrictions</b>             | 18 years of age or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | 14 days  |
| <b>Other Criteria</b>               | PA applies to all.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# LYNPARZA

## Products Affected

- LYNPARZA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, BRCA mutation status, documentation that the patient has been treated with three or more prior lines of chemotherapy, submission of baseline CBC and confirmation that CBC will be monitored monthly thereafter. |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to hematology and oncology prescribers   |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Mavyret (glecaprevir/pibrentasvir)

---

### Products Affected

- MAVYRET

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Patients with severe hepatic impairment (Child-Pugh class C or worse) and patients on rifampin or atazanavir                             |
| <b>Required Medical Information</b> | Diagnosis of covered use and laboratory confirmation of hepatitis C virus (HCV) as indicated consistent with current AASLD-IDSA guidance |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | 12 weeks   |
| <b>Other Criteria</b>               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# MEKINIST

## Products Affected

- MEKINIST

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of FDA- approved test confirming presence of BRAF V600E or V600K mutation, submission of baseline LVEF and confirmation that LVEF is scheduled to re-assessed after one month of treatment and then every 2 to 3 months thereafter, submission of blood pressure reading |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to oncology or hematology   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | Mekinist is not indicated for the treatment of patients who have received prior-BRAF-inhibitor therapy. PA applies to new starts only.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Methamphetamine

## Products Affected

- DESOXYN
- *methamphetamine hcl*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Exogenous Obesity- if this drug is being used for this indication, the drug is not covered as it is part of the excluded categories described in Chapter 6 Medicare Prescription Drug Manual Rev. 1-15-16.<br>Methamphetamine hydrochloride tablets are contraindicated during or within 14 days following the administration of monoamine oxidase inhibitors, in patients with glaucoma, advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism or known hypersensitivity or idiosyncrasy to sympathomimetic amines. Methamphetamine should not be given to patients who are in an agitated state or who have a history of drug abuse. |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of baseline blood pressure  |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | For patients 65 years of age and older- submission of documentation that provider is aware medication is considered a high risk medication for elderly patients according to the Centers for Medicare and Medicaid services and that the benefits of methamphetamine therapy outweighs the potential risks to the patient.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# Methotrexate Oral Solution (Xatmep)

## Products Affected

- XATMEP

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Pregnancy (if female)  |
| <b>Required Medical Information</b> | Diagnosis of covered use. For pJIA patients confirmation that member is intolerant of or had an inadequate response to first-line therapy. For ALL confirmation that medication is being used as a component of a combination chemotherapy maintenance regimen. Documentation that the patient/caregiver has been counseled on proper dosing technique and frequency of the medication, baseline CBS with platelets, LFT, and Serum Creatinine/eGFR have been obtained and will be monitored throughout therapy. |
| <b>Age Restrictions</b>             | 2 YO to 18 YO  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Methyl Testosterone Products

## Products Affected

- ANDROID
- *methitest*
- *methyltestosterone oral*
- TESTRED

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Male patients with carcinomas of the breast or prostate, female patients who are or may become pregnant   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, for male patients- documentation that patient has been evaluated for the presence of prostate cancer prior to initiation of therapy, for female patients diagnosed with disseminated breast carcinoma who are 1 to 5 years postmenopausal- submission of baseline urine and serum calcium levels and confirmation calcium levels will be monitored during the course of androgen therapy, submission of baseline X-ray bone age examination result of the hand or wrist in prepubertal male patients and confirmation re-examinations will be performed every 6 months, for all patients-submission of baseline HGB, HCT, ALT, AST and total bilirubin levels and confirmation liver function tests will continue to be monitored periodically while on therapy, submission of baseline GFR |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | one year  |
| <b>Other Criteria</b>               | For patients 65 years of age and older- submission of documentation that provider is aware medication is considered a high risk medication for elderly patients according to the Centers for Medicare and Medicaid services and that the benefits of methyltestosterone therapy outweighs the potential risks to the patient. PA applies to all.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Midostaurin (Rydapt)

### Products Affected

- RYDAPT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Patients on strong CYP3A4 inducers (i.e. Carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort)   |
| <b>Required Medical Information</b> | Diagnosis of covered use. Documentation of that the following baseline laboratory measurements are available and will be monitored throughout use: liver function tests, CBC with platelets, serum sodium and calcium levels. Documentation that the patient has been counseled to report any signs of pulmonary toxicity while on medication immediately and that consideration will be given to stopping medication if they are felt to be due to therapy with Midostaurin. If a male or female of reproductive potential, documentation that patient has been counseled to use effective contraception during treatment and for at least 4 months after the last dose of medication. |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology/Oncology  |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# MIRVASO

---

## Products Affected

- MIRVASO

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D. |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use and previous trial of azelaic acid            |
| Age Restrictions             | 18 YO or older   |
| Prescriber Restrictions      | limited to dermatology   |
| Coverage Duration            | one year   |
| Other Criteria               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# MOZOBIL

## Products Affected

- MOZOBIL

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of baseline CBC and platelet counts, confirmation medication is being used in combination with granulocyte-colony stimulating factor, submission of patient's current weight, submission of baseline serum creatinine level.   |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | limited to oncology and hematology  |
| <b>Coverage Duration</b>            | one treatment course (4 days of therapy)  |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: A physician/health care provider is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. This medication may be covered under Part B if administered by a physician incident to a physician service. PA applies to all |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## MULPLETA (lusutrombopag)

---

### Products Affected

- MULPLETA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use.   |
| <b>Age Restrictions</b>             | 18 years of age or older  |
| <b>Prescriber Restrictions</b>      | Restricted to hematology, gastroenterology, and surgery   |
| <b>Coverage Duration</b>            | 7 days  |
| <b>Other Criteria</b>               | PA applies to all. This medication should not be administered to patients with chronic liver disease in an attempt to normalize platelet counts and will not be approved for this indication. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# MYALEPT

## Products Affected

- MYALEPT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | patients with general obesity not associated with congenital leptin deficiency  |
| <b>Required Medical Information</b> | diagnosis of covered use, submission of patient weight, submission of leptin level laboratory test result confirming leptin deficiency, submission of baseline HbA1c, fasting glucose and fasting triglyceride levels |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | one year  |
| <b>Other Criteria</b>               | Continuation of approval requires submission of patient weight, updated HbA1c, fasting glucose and fasting triglyceride levels.PA applies to all.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Mylotarg

## Products Affected

- MYLOTARG INTRAVENOUS SOLUTION  
RECONSTITUTED 4.5 MG

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.   |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use demonstrating that patient has CD33-positive disease. Patients with a history of or predisposition for QTc prolongation have a baseline electrocardiogram (ECG) AND patients with hyperleukocytosis (leukocyte count greater than or equal $30 \times 10^9/L$ ) have had cytoreduction AND patient has not previously received gemtuzumab ozogamicin AND for patients with Acute Myeloid Leukemia (AML): Patient has newly-diagnosed disease AND Used in combination with daunorubicin and cytarabine AND Patient has de novo disease AND Patient does not have adverse-risk cytogenetics OR cytogenetic results are not yet known OR Used as a single agent OR patient has relapsed or refractory disease AND Must be used as a single agent. Confirmation that females of reproductive potential have been counseled to use effective contraception during treatment with gemtuzumab and for at least 6 months after the last dose. Males with female partners of reproductive potential have been counseled to use effective contraception during treatment with gemtuzumab and for at least 3 months after the last dose. Documentation of baseline laboratory analysis of the following which will be needed to determine if any potential medication-related adverse reactions are occurring: ALT, AST, total bilirubin, and alkaline phosphatase, and platelet counts. Also, confirmation that these labs will be drawn and monitored as required by package labeling. Confirmation that the patient will be premedicated to prevent infusion reactions as directed in package labeling. Additionally, confirmation must be given that the provider will appropriately monitor patients during infusions and for at least one (1) hour after each infusion in a setting that will allow for prompt treatment of any infusion-related reactions, should they occur. |
| Age Restrictions             |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



| <b>PA Criteria</b>             | <b>Criteria Details</b>  |
|--------------------------------|--|
| <b>Prescriber Restrictions</b> | requested by an oncologist or hematologist (or under the documented recommendation of an oncologist or hematologist)   |
| <b>Coverage Duration</b>       | One year   |
| <b>Other Criteria</b>          | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown-bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration, if the medication is being administered in the enrollee's home, there are no associated safety concerns with preparation and/or administration of the medication documented in the prescribing information and if the medication is being administered in the enrollee's home by a route other than orally or subcutaneously, documentation is provided that the member has been fully trained on how to administer the medication safely and effectively if applicable. If these conditions are not satisfied these medications may be covered under Part B in accordance with the corresponding NCD/LCD if applicable.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## MYTESI (crofelemer)

---

### Products Affected

- MYTESI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>Previously Fulyzaq |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use   |
| <b>Age Restrictions</b>             | 18YO or older  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to new starts   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Naglazyme

## Products Affected

- NAGLAZYME

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D   |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use, submission of patient weight, documentation that the healthcare setting and provider are prepared to manage infusion reactions including life-threatening anaphylaxis   |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: A a physician is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration If these conditions are not satisfied this medication may be covered under Part B. PA applies to new starts only. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# NAMZARIC

## Products Affected

- NAMZARIC

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.  |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered medical use, submission of documentation that the patient has been stabilized on memantine hydrochloride (5mg twice daily, 10mg twice daily, 14mg extended-release daily, or 28mg extended-release daily) and donepezil hydrochloride 10mg daily, submission of patient current weight and serum creatinine level for the purposes of calculating creatinine clearance |
| Age Restrictions             | 18 YO or older  |
| Prescriber Restrictions      |   |
| Coverage Duration            | one year  |
| Other Criteria               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# NATPARA

## Products Affected

- NATPARA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically-accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, prior to initiation of therapy documentation that serum calcium (albumin-corrected) is greater than 7.5 mg/dL and confirmation that 25-hydroxyvitamin D stores are sufficient, confirmation that serum calcium concentration will be measured every 3 to 7 days after starting or adjusting Natpara dose |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Natpara REMS program certified healthcare providers  |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | Patients and caregivers who will administer Natpara will receive appropriate training and instruction by a trained healthcare professional prior to the first use of Natpara   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## NERLYNX (neratinib)

### Products Affected

- NERLYNX

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Patients on Strong or Moderate CYP3A4 Inhibitors OR Inducers   |
| <b>Required Medical Information</b> | <p>Diagnosis of covered use and genetic tumor testing showing that the primary tumor type is HR Positive, HER2-Positive and that the member has completed adjuvant trastuzumab-based therapy. Additionally, the provider must attest that medication will be initiated along with loperamide as per package labeling guidelines and that the medication will be permanently stopped if grade 4 diarrhea should occur or Grade 2 or greater diarrhea that occurs after maximal dose reduction.</p> <p>Documentation of baseline laboratory values of liver function tests, CBC, serum creatinine must have been drawn and provider attests that LFT's will be drawn monthly for the first three months of treatment and then every three months thereafter. Also if a female of reproductive potential, the provider must attest counseling patient to use effective contraception during treatment and for at least 1 month after the last dose.</p> |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Hematology/Oncology   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# NEULASTA

---

## Products Affected

- NEULASTA ONPRO
- NEULASTA SUBCUTANEOUS SOLUTION  
PREFILLED SYRINGE

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           | PBPC Mobilization   |
| Required Medical Information | Diagnosis of Covered Use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | 6 Months  |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# NEXAVAR

---

## Products Affected

- NEXAVAR

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new strats only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# NINLARO

## Products Affected

- NINLARO

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, and documentation that medication will be administered concomitantly with lenalidomide and dexamethasone, documentation of prior therapy regimen for multiple myeloma, submission of baseline platelet count and absolute neutrophil count, submission of creatinine clearance or current body weight and serum creatinine level for the purposes of creatinine clearance calculation using the Cockcroft-Gault equation, submission of baseline LFTs and bilirubin |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology and Oncology  |
| <b>Coverage Duration</b>            | 3 months initially, then annually thereafter  |
| <b>Other Criteria</b>               | Documentation of platelet count greater than 30,000/mm <sup>3</sup> , ANC greater than 500/mm <sup>3</sup> , and Grade 1 or lower non-hematological toxicities (including rash, peripheral neuropathies) required for continuation of approval. Submission of documentation of patient's hepatic (serum bilirubin and LFTs) and renal function (creatinine clearance) is required annually. PA Applies to New Starts Only.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# NORTHERA

---

## Products Affected

- NORTHERA

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D. |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use   |
| Age Restrictions             | 18 years of age  |
| Prescriber Restrictions      |  |
| Coverage Duration            | 2 weeks initially, then 1 year   |
| Other Criteria               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# NUCALA

## Products Affected

- NUCALA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | History of hypersensitivity to mepolizumab or excipients in the formulation   |
| <b>Required Medical Information</b> | Diagnosis of covered use of treatment of severe asthma in patients with eosinophilic phenotype, submission of pulmonary function test results including FEV1, submission of blood eosinophil count documenting 150 cells/mcL obtained within 6 weeks prior to therapy initiation or 300 cells/mcL within 12 months of therapy initiation, submission of documentation that patient's symptoms are poorly controlled with inhaled corticosteroids, frequency of inhaled short-acting beta2-agonist therapy, submission of frequency of daily and nighttime symptoms and exacerbations, effect of exacerbations on activity. Confirmation that the patient will receive treatment in the doctor's office or clinic and be observed for an appropriate amount of time after each treatment, documentation that the healthcare setting and providers are prepared to manage life-threatening anaphylaxis. |
| <b>Age Restrictions</b>             | 12 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Allergy, Pulmonology, or Immunology  |
| <b>Coverage Duration</b>            | One Year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | Continuation of therapy requests require objective documentation from the prescriber that the patient's symptoms have improved. The medication may be covered under Part D provided the following conditions are satisfied: A physician is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or clinic for administration. If these conditions are not satisfied, the medication may be covered under Part B. PA Applies to All. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# NULOJIX (belatacept)

## Products Affected

- NULOJIX

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Kidney transplant: The medication is being used for prevention of kidney transplant organ rejectionAND The patient is immune to the Epstein-Barr virus (i.e. EBV seropositive) AND The patient isprescribed concurrent therapy with mycophenolate and corticosteroids   |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Prescriber is experienced in immunosuppressive therapy and management oftransplant patients   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown-bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office for administration, if the medication is being self-administered documentation is provided that the enrollee has been fully trained on how to prepare the injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. Additionally provider must attest that medication will be given under conditions where they may be monitored for hypersensitivity reactions. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# NUPLAZID

## Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG, 17 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, confirmation patient does not have severe renal impairment or hepatic impairment   |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | Continuation of approval requires documentation of a patient's positive response to therapy including a decrease in the frequency and/or severity of hallucinations and delusions or a maintenance of the initial response to therapy<br>PA applies to ALL |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# NYMALIZE

## Products Affected

- NYMALIZE ORAL SOLUTION 30 MG/10ML

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.   |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use. Attestation by the provider of the following: medication is being started within 96 hours of the subarachnoid hemorrhage and will be continued for 21 consecutive days, blood pressures will be frequently monitored throughout therapy. If the patient is also on a strong CYP3A4 inhibitor or inducer, the provider must provide a clinical rationale for how they are mitigating the risks of either increased clearance of nimodipine or increased levels of nimodipine. If the member is known or suspected to have cirrhosis, a clinical rationale must be provided for how the provider is mitigating the risks of adverse events to the patient. |
| Age Restrictions             | 18 YO or older   |
| Prescriber Restrictions      |  |
| Coverage Duration            | 21 Days  |
| Other Criteria               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# OCALIVA

## Products Affected

- OCALIVA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Patients with complete biliary obstruction  |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, documentation that Ocaliva will be used in combination with ursodeoxycholic acid (UDCA) in adult patients who have failed to achieve an adequate response to at least one year of UDCA monotherapy or if Ocaliva is being prescribed as monotherapy, documentation patient is unable to tolerate UDCA, submission of baseline LFTs including ALP and total bilirubin, submission of baseline lipid levels including HDL-C and confirmation patient will be monitored for changes in serum lipid levels while on therapy |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | Submission of ALP, total bilirubin and HDL-C obtained within the previous 3 months is required for continuation of therapy. PA Applies to All.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# ODOMZO

## Products Affected

- ODOMZO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of baseline serum creatinine kinase (CK) and creatinine levels and confirmation that these levels will be monitored periodically during treatment, documentation that female patient of reproductive potential is not pregnant prior to therapy initiation and confirmation that females of reproductive potential have been advised to use highly effective contraception during treatment and for at least 20 months after the last dose, confirmation that male patients with female partners have been advised to use condoms, even after a vasectomy, during treatment and for at least 8 months after the last dose |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Hematology or Oncology  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA Applies to New Starts   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# OPDIVO

## Products Affected

- OPDIVO INTRAVENOUS SOLUTION 100 MG/10ML, 40 MG/4ML

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically-accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission of baseline LFTs (including AST, ALT, and total bilirubin), baseline serum creatinine, baseline thyroid function tests, submission of patient current weight, documentation patient with unresectable or metastatic melanoma has experienced disease progression following ipilimumab and if BRAF V600 mutation positive, a BRAF inhibitor, documentation patient with metastatic squamous non-small cell lung cancer has experienced disease progression on or after platinum-based chemotherapy |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Hematology/Oncology prescribers   |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# OPSUMIT

## Products Affected

- OPSUMIT

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Pregnancy  |
| <b>Required Medical Information</b> | Diagnosis of covered use, negative pregnancy test result for female patients of childbearing age and confirmation pregnancy will be excluded monthly during treatment and for 1 month after stopping treatment, submission of baseline AST, ALT and bilirubin levels, and submission of baseline HGB level and confirmation that these lab values will be monitored during treatment as clinically indicated |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to pulmonologists and cardiologists  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ORALAIR

## Products Affected

- ORALAIR

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Severe, unstable or uncontrolled asthma, history of any severe systemic allergic reaction, history of any severe local reaction to sublingual allergen immunotherapy, hypersensitivity to mannitol, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica, magnesium stearate or lactose monohydrate   |
| <b>Required Medical Information</b> | Oralair is being requested for the treatment of grass pollen induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for any of the following grass species: Sweet Vernal, Orchard, Perennial Rye, Timothy and Kentucky Blue Grass, therapy is being initiated 4 months before the expected onset of each grass pollen season, confirmation that the first dose of medication will be administered in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of severe allergic reactions and that the patient will be observed for at least 30 minutes after administration of the first dose to monitor for signs and symptoms of a severe systemic or severe local allergic reaction. |
| <b>Age Restrictions</b>             | Patients 10 through 65 years of age  |
| <b>Prescriber Restrictions</b>      | Limited to allergy and immunology  |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | Confirmation auto-injectable epinephrine therapy has been prescribed and patient has been instructed on the proper use of emergency self-injection epinephrine. PA applies to all.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ORBACTIV

## Products Affected

- ORBACTIV

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | patients with known medical need for intravenous unfractionated heparin sodium within 120 hours (5 days) of Orbactiv administration   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of culture proven infection caused by susceptible isolates of one of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant MRSA) and methicillin-susceptible (MSSA) isolates, Streptococcus pyogenes, Streptococcus agalactiae, streptococcus dysgalactiae, Streptococcus anginosus Group(including Streptococcus anginosus, intermedius and constellatus), and Enterococcus faecalis (vancomycin-susceptible isolates only), confirmation Orbactiv will be administered by IV infusion over at least 3 hours |
| <b>Age Restrictions</b>             | 18 years of age or older  |
| <b>Prescriber Restrictions</b>      | Limited to infectious disease specialists   |
| <b>Coverage Duration</b>            | one dose  |
| <b>Other Criteria</b>               | If this medication is being administered in the enrollee's home via an infusion pump it is covered as a Part B benefit. If it being administered in the enrollee's home via IV drip it is covered as a Part D benefit. Serious hypersensitivity reactions and infusion related reactions have been reported. Healthcare professional and place of administration must be properly trained on how to prepare and administer the medication and be equipped to treat hypersensitivity and infusion related reactions. PA Applies to All.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ORENITRAM

## Products Affected

- ORENITRAM ORAL TABLET EXTENDED  
RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5 MG,  
5 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | idiopathic pulmonary fibrosis, including idiopathic pulmonary fibrosis patients with pulmonary hypertension or WHO group 3.   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of baseline AST, ALT and bilirubin levels, submission of baseline HGB level and confirmation HGB will be measured after 1 month of therapy and periodically thereafter |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Pulmonologists and Cardiologists   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ORFADIN

## Products Affected

- ORFADIN

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D  |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use, urine succinylacetone levels, liver function tests, alpha-fetoprotein level, serum tyrosine level, serum phenylalanine level, patient weight |
| Age Restrictions             |  |
| Prescriber Restrictions      |  |
| Coverage Duration            | 6 months   |
| Other Criteria               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## ORILISSA (elagolix)

### Products Affected

- ORILISSA ORAL TABLET 150 MG, 200 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Pregnancy, severe (Child-Pugh class C) hepatic impairment, known osteoporosis  |
| <b>Required Medical Information</b> | Diagnosis of covered use.  |
| <b>Age Restrictions</b>             | 18 years of age or older   |
| <b>Prescriber Restrictions</b>      | Restricted to endocrinology and gynecology   |
| <b>Coverage Duration</b>            | Up to 24 months based on liver function and coexisting dyspareunia. See "Other Criteria" section.  |
| <b>Other Criteria</b>               | PA applies to all. For endometriosis with dyspareunia or in women with moderate hepatic impairment, up to 6 months. For endometriosis without dyspareunia, 150 mg daily up to 24 months. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# ORKAMBI

## Products Affected

- ORKAMBI ORAL TABLET

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, documentation that the patient is homozygous for the F508del mutation in the CFTR gene provided from an FDA-cleared CF mutation test, submission of baseline AST/ALT, bilirubin, and documentation of the patients ppFEV1, submission of documentation that baseline and follow-up ophthalmologic exams will be performed in pediatric patients starting on therapy. |
| <b>Age Restrictions</b>             | 12 years of age and older  |
| <b>Prescriber Restrictions</b>      | Limited to Pulmonology   |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | Submission of documentation the liver function tests will be assessed every 3 months during the first year of treatment, and annually thereafter. Additional monitoring may be required for patients with ppFEV1 less than 40 percent.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# OTREXUP

## Products Affected

- OTREXUP SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.4ML, 12.5 MG/0.4ML, 15 MG/0.4ML, 17.5 MG/0.4ML, 20 MG/0.4ML, 22.5 MG/0.4ML, 25 MG/0.4ML

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Pregnancy, treatment of nursing mother, patient with alcoholism or liver disease, patient with immunodeficiency syndromes or preexisting blood dyscrasias   |
| <b>Required Medical Information</b> | Diagnosis of covered use, documentation of other therapies tried and patient response, submission of negative pregnancy test result for women of reproductive potential, submission of baseline complete blood counts, renal function tests, liver functions tests and confirmation that complete blood counts, renal function tests and liver function tests are scheduled to be monitored periodically while on therapy, submission of pediatric patient weight |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | Limited to rheumatologists or dermatologists  |
| <b>Coverage Duration</b>            | one year  |
| <b>Other Criteria</b>               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## PALYNZIQ (pegvaliase-pqpz)

### Products Affected

- PALYNZIQ

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of blood phenylalanine concentration.   |
| <b>Age Restrictions</b>             | 18 years of age or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | 1 year   |
| <b>Other Criteria</b>               | PA applies to all. Continuation of therapy after 1 year requires documentation of blood phenylalanine concentration below 600 micromol/L or at least a 20% reduction in blood phenylalanine concentration from pre-treatment baseline. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# PCSK-9 Inhibitor

## Products Affected

- PRALUENT SUBCUTANEOUS SOLUTION PEN-INJECTOR
- REPATHA
- REPATHA PUSHTRONEX SYSTEM
- REPATHA SURECLICK

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use as medically indicated for the treatment of heterozygous familial hypercholesterolemia (HeFH) or ASCVD. If medication is required for the treatment of HeFH, documentation of genetic test result documenting HeFH or diagnosis by clinical criteria using Simon Broom or WHO/Dutch Lipid Network criteria, and submission of documentation that medication is being used with maximally tolerated statin therapy, or documentation of inability to tolerate statin therapy (with at least one hydrophilic statin having been tried and failed). If requested for treatment of ASCVD, patient has history of one of the following: MI, ACS, stable or unstable angina, coronary or other arterial revascularization, stroke, TIA, PAD or ASCVD risk score is equal to or greater than 7.5% and documentation that medication is being used as an adjunct to maximally tolerated statin therapy, or documentation of inability to tolerate statin therapy (with at least one hydrophilic statin having been tried and failed). Submission of LDL level obtained within the previous 6 months and providers stated LDL-C goal. |
| <b>Age Restrictions</b>             | 13 YO or older  |
| <b>Prescriber Restrictions</b>      | The authorization must be submitted by or under the documented recommendation of a cardiologist, lipidologist, or endocrinologist with experience and focus on lipid management   |
| <b>Coverage Duration</b>            | Six months initially, then one year thereafter  |
| <b>Other Criteria</b>               | Submission of LDL level documenting clinically significant response to therapy will be required for reauthorization.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## PEGYLATED INTERFERONS/RIBAVIRIN

### Products Affected

- MODERIBA 1200 DOSE PACK
- MODERIBA 800 DOSE PACK
- MODERIBA ORAL TABLET 200 MG
- PEGASYS PROCLICK
- PEGASYS SUBCUTANEOUS SOLUTION
- PEGINTRON SUBCUTANEOUS KIT 50 MCG/0.5ML
- REBETOL
- RIBASPHERE
- RIBASPHERE RIBAPAK ORAL TABLET 400 MG, 600 MG
- RIBASPHERE RIBAPAK ORAL TABLET THERAPY PACK
- *ribavirin oral capsule*
- *ribavirin oral tablet 200 mg*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | For pegylated interferon therapy-automimmune hepatitis, hepatic decompensation (Child-Pugh score greater than 6 [class B and C]) in cirrhotic CHC patients before or during treatment, for ribavirin therapy- women who are or may become pregnant or men whose female partners are pregnant, patients diagnosed with hemoglobinopathies (thalassemia majore, sickel-cell anemia), creatinine clearance less than 50ml/min  |
| <b>Required Medical Information</b> | Diagnosis of Covered Use and submission of Lab values (HCV RNA level, ALT, AST, genotype), patient weight, for patients receiving combination therapy with ribavirin- submission of neagative preganancy test result prior to therapy, documentation that at least two forms of contraception will be used during treatment and that patient will undergo monthly pregnancy tests, submission of current (obtained within the previous three months) serum creatinine level to calculate creatinine clearance |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | 48 weeks  |
| <b>Other Criteria</b>               | Coverage duration may vary based on indication. PA applies to all.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# POMALYST

---

## Products Affected

- POMALYST

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Pregnancy   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of baseline laboratory values including serum creatinine, serum bilirubin, AST and ALT, CBC including ANC and platelet count |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to oncology or hematology   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## POTELIGEO (mogamulizumab-kpkc)

### Products Affected

- POTELIGEO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.                           |
| <b>Exclusion Criteria</b>           | Pregnancy  |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation of use of one prior systemic therapy for the covered use. |
| <b>Age Restrictions</b>             | 18 years of age or older   |
| <b>Prescriber Restrictions</b>      | Restricted to hematology and oncology  |
| <b>Coverage Duration</b>            | 1 year   |
| <b>Other Criteria</b>               | PA applies to new starts only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Prevymis (letermovir)

## Products Affected

- PREVYMIS ORAL

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Patients on pimozide, ergot alkaloids, or those who will be taking a combination of letermovir, cyclosporine, AND simvastatin OR pitavastatin                               |
| <b>Required Medical Information</b> | Diagnosis of covered use.   |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to hematology/oncology/infectious disease   |
| <b>Coverage Duration</b>            | Up to 100 days per HSCT   |
| <b>Other Criteria</b>               | The provider must attest to what day post HSCT patient is and if the patient has received any previous doses of letermovir to allow for an appropriate duration of therapy. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



## Prior Auth to Override Specialty Restrictions

### Products Affected

- *acitretin*
- APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE
- CRINONE
- FABIOR
- ICLUSIG
- *mitomycin intravenous*
- NUEDEXTA
- SYLATRON SUBCUTANEOUS KIT 200 MCG, 300 MCG, 600 MCG
- TACLONEX EXTERNAL OINTMENT
- *tazarotene external*
- TAZORAC
- VABOMERE
- VALCHLOR
- XYREM

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | Physicians who specialize in the treatment of medical conditions most commonly treated with this medication are exempt from prior authorization. PA applies to new starts only. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# PROCRIT

## Products Affected

- PROCRIT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use. Lab values from bloodwork indicating hemoglobin and iron levels. Blood pressure is also required. |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | 3 Months  |
| <b>Other Criteria</b>               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# PROCYSBI

## Products Affected

- PROCYSBI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.             |
| <b>Exclusion Criteria</b>           | Hypersensitivity to cysteamine, penicillamine, or any component of the formulation |
| <b>Required Medical Information</b> | Diagnosis of covered use   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Promacta

## Products Affected

- PROMACTA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, previous therapies tried (corticosteroids, immunoglobulins), lab values (including ALT, AST, bilirubin, CBC with differentials and platelet count) |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | six months   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# PROMETHAZINE VC

## Products Affected

- *promethazine vc plain oral solution*
- *promethazine-phenylephrine*

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.   |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use including treatment of medical condition causing a cough, not due to symptomatic relief of cough and/or cold. |
| Age Restrictions             |  |
| Prescriber Restrictions      |  |
| Coverage Duration            | One Year   |
| Other Criteria               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## PROVIGIL/NUVIGIL

### Products Affected

- *modafinil*
- PROVIGIL

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D   |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use and sleep latency test results may be required |
| Age Restrictions             | 17 YO or older  |
| Prescriber Restrictions      |   |
| Coverage Duration            | one year  |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Purified Proteinase Inhibitor

## Products Affected

- ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG
- GLASSIA
- PROLASTIN-C INTRAVENOUS SOLUTION
- ZEMAIRA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Individuals with immunoglobulin A (IgA) deficiency who have known antibodies against IgA, patients who have previously demonstrated hypersensitivity, anaphylaxis or severe systemic response to alpha1-proteinase inhibitor products  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient body weight, confirmation that patient has clinically evident emphysema secondary to congenital alpha-PI deficiency by submission of pulmonary function testing (e.g. spirometry or body plethysmography), X-ray radiography or Diffusing capacity of the lung for carbon monoxide (DLCO).   |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to pulmonology   |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician or health care provider is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office, infusion center or homecare provider for administration, if the medication is being self-administered documentation is provided that the enrollee has been fully trained on how to prepare the injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B. PA applies to new starts only. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## RADICAVA (edaravone)

### Products Affected

- RADICAVA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use   |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Neurology   |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown-bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office for administration, if the medication is being self-administered documentation is provided that the enrollee has been fully trained on how to prepare the injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. Additionally, provider must attest that medication will be given under conditions where they may be monitored for hypersensitivity reactions. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# RAGWITEK

## Products Affected

- RAGWITEK

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Severe, unstable or uncontrolled asthma, history of any severe systemic allergic reaction or any severe local reaction to sublingual allergen immunotherapy, history of eosinophilic esophagitis, hypersensitivity to gelatin, mannitol, or sodium hydroxide   |
| <b>Required Medical Information</b> | Ragwitek is being requested for the treatment of grass pollen induced allergic rhinitis with or without conjunctivitis confirmed by positive skin test or in vitro testing for pollen-specific IgE antibodies for short ragweed pollen, therapy is being initiated at least 12 weeks before the expected onset of ragweed pollen season, confirmation that the first dose of medication will be administered in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases and that the patient will be observed for at least 30 minutes after administration of the first dose to monitor for signs and symptoms of a severe systemic or severe local allergic reaction. |
| <b>Age Restrictions</b>             | Patients 18 through 65 years of age  |
| <b>Prescriber Restrictions</b>      | Limited to allergy and immunology  |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | Confirmation auto-injectable epinephrine therapy has been prescribed and patient has been instructed on the proper use of emergency self-injection epinephrine. PA applies to all.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# RASUVO

## Products Affected

- RASUVO SUBCUTANEOUS SOLUTION AUTO-INJECTOR 10 MG/0.2ML, 12.5 MG/0.25ML, 15 MG/0.3ML, 17.5 MG/0.35ML, 20 MG/0.4ML, 22.5 MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML, 7.5 MG/0.15ML

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Contraindicated in pregnancy, nursing mothers, alcoholism or liver disease, immunodeficiency syndromes, preexisting blood dyscrasias, hypersensitivity to methotrexate, treatment of neoplastic conditions  |
| <b>Required Medical Information</b> | Diagnosis of covered use, documentation of intolerance or inadequate response to first-line therapy, submission of complete blood count (CBC)with differential and platelet count, submission of baseline hepatic enzymes, renal function tests and a chest X-ray, submission of current height and weight for pediatric patients for the purposes of dosage verification |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      | limited to rheumatology or dermatology  |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# RAVICTI

## Products Affected

- RAVICTI

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | patients with a known hypersensitivity to phenylbutyrate  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient's height and current weight for dose verification purposes, submission of baseline fasting plasma ammonia level |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | remainder of the contract year  |
| <b>Other Criteria</b>               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Remodulin

## Products Affected

- REMODULIN

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use, submission of patient weight                |
| Age Restrictions             |   |
| Prescriber Restrictions      | Limited to pulmonology or cardiology                                  |
| Coverage Duration            | One Year  |
| Other Criteria               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# REVATIO

## Products Affected

- REVATIO
- *sildenafil citrate intravenous*
- *sildenafil citrate oral tablet 20 mg*

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use  |
| Age Restrictions             |   |
| Prescriber Restrictions      | Limited to Pulmonologists/Cardiologists                               |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# REVLIMID

## Products Affected

- REVLIMID

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use, pregnancy negative, Lab values (CBC)        |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# RITUXAN

## Products Affected

- RITUXAN INTRAVENOUS SOLUTION

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically-accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation that patient does not have a severe, active infection and for the treatment of rheumatoid arthritis- the patient is diagnosed with moderately-to severely active RA, the number of swollen and tender joints is submitted, the patient has tried and failed to achieve an adequate response to at least one prior TNF antagonist therapy, submission of confirmation that patient will receive concurrent methotrexate therapy and submission of one of the following: CRP, sed rate or rheumatoid factor,for the treatment of Wegener's Granulomatosis (GPA)- medication is requested to be used in combination with glucocorticoid therapy,for the treatment of GPA, NHL and CLL submission of patient's height and current weight, for the treatment of NHL and CLL- baseline CBC including platelet count is submitted, for the treatment of CLL medication is requested to be used in combination with fludarabine and cyclophosphamide (FC) |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | For RA-6 months all other diagnoses-1 year   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>Approval for the treatment of RA will be two 1000mg IV infusions separated by 2 weeks (days 1 and 15), in combination with methotrexate. Retreatment for RA may be considered after 16 weeks provided patient has demonstrated a positive clinical response based on the required baseline objective clinical measures. If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration, if the medication is being administered in the enrollee's home, there are no associated safety concerns with preparation and/or administration of the medication documented in the prescribing information and documentation is provided that the member has been fully trained on how to administer the medication safely and effectively if applicable. If these conditions are not satisfied the medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. PA applies to new starts only.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



## RUBRACA (rucaparib)

### Products Affected

- RUBRACA

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.   |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use, documentation of deleterious BRCA mutation as detected by FDA approved companion diagnostic test, documentation that the patient has been treated with two or more chemotherapies, confirmation that female patients of reproductive potential have been advised to use effective contraception during treatment and for 6 months after the last dose of Rubraca, confirmation patients will be monitored for hematologic toxicity at baseline and monthly thereafter while on therapy |
| Age Restrictions             | 18 YO or older   |
| Prescriber Restrictions      |  |
| Coverage Duration            | One Year   |
| Other Criteria               | PA Applies to New Starts Only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# RUCONEST

## Products Affected

- RUCONEST

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Known or suspected allergy to rabbits and rabbit-derived products, history of immediate hypersensitivity to C1 esterase inhibitors  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient's current weight, confirmation treatment will be initiated under the supervision of a qualified healthcare professional experienced in the treatment of hereditary angioedema |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | Plan Year   |
| <b>Other Criteria</b>               | Member has been instructed on proper administration technique if self-administering. PA applies to new starts only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SAMSCA

---

## Products Affected

- SAMSCA

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use and Lab Values (Serum sodium)                |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | 30 days   |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Sedating antihistamines

### Products Affected

- *carbinoxamine maleate oral solution*
- *carbinoxamine maleate oral tablet 4 mg*
- *clemastine fumarate oral tablet 2.68 mg*
- *diphenhydramine hcl oral elixir*
- *promethazine hcl injection*
- *promethazine hcl oral syrup*
- *promethazine hcl oral tablet*
- *promethazine hcl rectal*
- *promethegan rectal suppository 25 mg*
- PROMETHEGAN RECTAL SUPPOSITORY 50 MG

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | 1)Must have a current diagnosis requiring the use of a sedating antihistamine such as allergic conjunctivitis, rhinitis, puritis, rhinorrhea, angioedema, urticaria, or a severe allergic reaction AND2)Patient must have tried and failed or had an inadequate response to a second generation antihistamine such as cetirizine or loratadine and 3)Documentation is submitted confirming that the provider is aware the medication is considered a high risk medication for elderly patients according to the Centers for Medicare and Medicaid services and5)justification is submitted which explains the benefits of the identified drug and how that benefit outweighs the potential risks to the patient. |
| <b>Age Restrictions</b>             | PA applies to patients 65 YO or older. PA does not apply to patients 64 YO or younger  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Self Injectable Drug Policy

## Products Affected

- ACTIMMUNE
- ELIGARD
- *leuprolide acetate injection*
- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)
- LUPRON DEPOT-PED (1-MONTH)  
INTRAMUSCULAR KIT 11.25 MG, 15 MG
- LUPRON DEPOT-PED (3-MONTH)  
INTRAMUSCULAR KIT 30 MG (PED)
- *octreotide acetate injection solution* 100 mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50 mcg/ml, 500 mcg/ml
- SANDOSTATIN INJECTION SOLUTION 100 MCG/ML, 1000 MCG/ML, 50 MCG/ML, 500 MCG/ML
- SANDOSTATIN LAR DEPOT

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SEROSTIM

---

## Products Affected

- SEROSTIM SUBCUTANEOUS SOLUTION  
RECONSTITUTED 4 MG, 5 MG, 6 MG

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use, patient height and weight                   |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SIGNIFOR

## Products Affected

- SIGNIFOR

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of the following lab values- fasting plasma glucose, hemoglobin A1c, ALT, aspartate aminotransferase, alkaline phosphatase, total bilirubin, TSH, free T4, GH/IGF-1, 24-hour urinary free cortisol, submission of ECG results, submission of gallbladder ultrasound results |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SIMVASTATIN HIGH DOSE

## Products Affected

- ZOCOR ORAL TABLET 80 MG

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Any new start to therapy: not recommended as initial therapy nor for patients already taking lower doses of simvastatin whose response is not adequate, coadministration with strong cytochrome P450 (CYP-450) 3A4 inhibitors (eg, itraconazole, ketoconazole, posaconazole, voriconazole, HIV protease inhibitors, boceprevir, telaprevir, erythromycin, clarithromycin, telithromycin, nefazodone, cobicistat-containing products), gemfibrozil, cyclosporine, or danazol, patients with active liver disease, nursing mothers, women who are pregnant or may become pregnant   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of documentation that patient has been taking simvastatin for 12 months or longer without ill effect, submission of current (obtained within the previous 12 months) lipid panel including HDL, LDL and triglyceride levels, submission of current (obtained within the previous 12 months) liver function tests including ALT, AST and total bilirubin, submission of current (obtained within the previous three months) serum creatinine level and patient weight, for women of childbearing age submission of negative pregnancy test result and documentation that patient has been counseled about the potential hazards of therapy if pregnancy occurs, |
| <b>Age Restrictions</b>             | 10 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# SIRTURO

## Products Affected

- SIRTURO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded by Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation that patient will receive at least 3 other drugs in combination with Sirturo to which the patient's infection has been shown to be susceptible, submission of baseline ECG and confirmation that ECG will be obtained at 2, 12 and 24 weeks after starting therapy, submission of baseline serum potassium, calcium and magnesium levels, submission of baseline ALT, AST, alkaline phosphatase and bilirubin and confirmation these lab values will be obtained monthly while on treatment |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to infectious disease specialist   |
| <b>Coverage Duration</b>            | 24 weeks   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SIVEXTRO

## Products Affected

- SIVEXTRO

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of culture proven infection caused by susceptible isolates of one of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant MRSA) and methicillin-susceptible (MSSA) isolates, Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus anginosus, intermedius and constellatus), and Enterococcus faecalis, submission of baseline neutrophil count documenting at least 1000 cells/mm <sup>3</sup> . |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to infectious disease specialist  |
| <b>Coverage Duration</b>            | 6 days of therapy   |
| <b>Other Criteria</b>               | If this medication is being administered in the enrollee's home via an infusion pump it is covered as a Part B benefit. If it being administered in the enrollee's home via IV drip it is covered as a Part D benefit. PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Skeletal Muscle Relaxants

## Products Affected

- AMRIX
- *chlorzoxazone oral tablet 500 mg*
- *cyclobenzaprine hcl oral*
- FEXMID
- *metaxall*
- *metaxalone*
- *methocarbamol oral*
- SKELAXIN

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | For diagnosis of fibromyalgia, coverage will be provided for cyclobenzaprine for patients who have tried and failed to tolerate or had an inadequate response to at least two of the following: gabapentin, fluoxetine, pregabalin, or milnacipran. For treatment of acute, painful musculoskeletal conditions, coverage will be provided when the prescriber attests to understanding the risks of skeletal muscle relaxants in the elderly, which include increased risk of fall and fracture due to sedation and anticholinergic effects. Additionally, the prescriber must attest to how the benefits outweigh the risks for the specific patient. |
| <b>Age Restrictions</b>             | PA applies to patients 65 YO or older. PA does not apply to patients 64 YO or younger  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to all.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## SOLARAZE diclofenac gel

---

### Products Affected

- *diclofenac sodium transdermal gel 3 %*

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.   |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use which includes the topical treatment of actinic keratoses (AK), confirmation that patient has been instructed to avoid sun exposure during treatment. |
| Age Restrictions             | 18yo or older  |
| Prescriber Restrictions      | limited to dermatology   |
| Coverage Duration            | 90 Days  |
| Other Criteria               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SOMATULINE DEPOT

## Products Affected

- SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 120 MG/0.5ML, 60 MG/0.2ML, 90 MG/0.3ML

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded by Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of serum GH and IGF-1 levels, documentation of degree of control of clinical acromegaly symptoms patient has, submission of TSH and blood glucose levels  |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | limited to endocrinologist or oncology   |
| <b>Coverage Duration</b>            | 3 months initially then up to one year   |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office for administration, if the medication is being self-administered by the enrollee documentation is provided that the member has been fully trained on how to prepare the medication for injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SOMAVERT

## Products Affected

- SOMAVERT

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, submission of the following baseline laboratory values: IGF-1, ALT, AST, ALP and serum total bilirubin         |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Endocrinologist   |
| <b>Coverage Duration</b>            | one year   |
| <b>Other Criteria</b>               | Continuation of therapy requests require submission of updated IGF-1, ALT, AST, ALP and serum total bilirubin levels. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SOVALDI

## Products Affected

- SOVALDI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use and laboratory confirmation of hepatitis C virus (HCV) as indicated consistent with current AASLD-IDSA guidance |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | 24 weeks based on genotype or 48 weeks for hepatocellular carcinoma pts awaiting transplant  |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SPRYCEL

## Products Affected

- SPRYCEL

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, documentation of prior therapy (except for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase) for Philadelphia chromosome-positive acute lymphoblastic leukemia and chronic, accelerated, or myeloid or lymphoid blast phase Philadelphia chromosome-positive chronic myeloid leukemia, CBC including platelet count and ANC. |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Oncologists/Hematologists.   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# STIVARGA

## Products Affected

- STIVARGA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of the following laboratory tests: ALT, AST, serum bilirubin, submission of baseline blood pressure reading |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | limited to oncologists/hematologists   |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# STRENSIQ

## Products Affected

- STRENSIQ

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.  |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of perinatal, infantile, or juvenile onset hypophosphatasia (HPP), submission of body weight for the purposes of dosage calculation, documentation that patient has been trained on proper injection technique, submission of baseline ophthalmology examination and renal ultrasound and confirmation these will be monitored periodically during treatment. |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA Applies to All   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SUCRAID

## Products Affected

- SUCRAID

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Sutent

## Products Affected

- SUTENT

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## SYMDEKO (tezacaftor/ivacaftor)

### Products Affected

- SYMDEKO

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use. Documentation that the patient is homozygous for the F508del mutation or has at least one mutation in the CTFR gene responsive to the drug (see section 12.1, table 4 of package insert for full list) provided from an FDA-cleared CF mutation test. Submission of baseline AST, ALT, and bilirubin. Submission of documentation that baseline and follow-up ophthalmologic exams will be performed in pediatric patients starting on therapy. |
| <b>Age Restrictions</b>             | 12 years of age or older  |
| <b>Prescriber Restrictions</b>      | Restricted to pulmonology   |
| <b>Coverage Duration</b>            | 1 year  |
| <b>Other Criteria</b>               | PA applies to all.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## SYMLIN

### Products Affected

- SYMLINPEN 120 SUBCUTANEOUS SOLUTION  
PEN-INJECTOR
- SYMLINPEN 60 SUBCUTANEOUS SOLUTION  
PEN-INJECTOR

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D                           |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use, HbA1C, previous or current use of an insulin                          |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | Endocrinologists are exempt from PA. PA applies to all except when prescribed by endocrinology. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Symproic (naldemedine)

---

### Products Affected

- SYMPROIC

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Known or suspected gastrointestinal obstruction or increase risk of obstruction  |
| <b>Required Medical Information</b> | Diagnosis of Covered use and confirmation that patient has been on at least 30mg Morphine daily dose (or equivalent) for at least four weeks prior to initiation and the provider must attest that if the opioid medication is stopped for any reason they will discontinue the naldemedine. |
| <b>Age Restrictions</b>             | 18 yo or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# SYNAGIS

## Products Affected

- SYNAGIS

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient's current weight. For the treatment of BPD- patient is 24 months of age or less at the start of Synagis season, patient required ventilatory support or supplemental oxygen beyond 36 weeks gestational age, within the six months preceding Synagis administration infant had one or more of the following clinical needs-Daily use of inhaled or oral bronchodilators, Recent use of oral or inhaled corticosteroid therapy or Regular or intermittent use of diuretics to treat pulmonary disease. For the treatment of CHD-patient is 24 months of age or less at the start of Synagis season, patient is receiving medication to control congestive heart failure or patient has moderate to severe pulmonary hypertension or patient has cyanotic heart disease. For patients with a history of premature birth-submission of patient's gestational age at birth. For patients 28 weeks gestational age at birth or less patient is 12 months of chronological age or less at the start of Synagis season, for patients 29 ? 32 weeks gestation age at birth patient is less than 6 months of chronological age at the start of Synagis season, for patients 32 weeks, 0 days through 34 weeks, 6 days gestation age at birth, patient was born less than three months prior to the start of Synagis season or is born during the RSV season and one of the following two risk factors is present: Currently attends day care or has a sibling younger than 5 years of age. |
| <b>Age Restrictions</b>             | patients up to 24 months of age   |
| <b>Prescriber Restrictions</b>      |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



| PA Criteria              | Criteria Details   |
|--------------------------|--|
| <b>Coverage Duration</b> | One complete season (as defined by respective community)   |
| <b>Other Criteria</b>    | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: A physician/health care provider is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. This medication may be covered under Part B if administered by a physician incident to a physician service. Synagis may be authorized for a maximum of five doses (one complete season) from November 1st-March 31st depending on patient diagnosis, history of prematurity and when during the RSV season treatment is begun. PA applies to all.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## SYNAREL

---

### Products Affected

- SYNAREL

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## SYPRINE

### Products Affected

- *trientine hcl*

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use and intolerant to penicillamine              |
| Age Restrictions             | 6 YO and older  |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# TAFINLAR

## Products Affected

- TAFINLAR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of FDA- approved test confirming presence of BRAF V600E or V600K mutation, documentation is submitted stating female patient of reproductive potential has been advised to use a highly effective non-hormonal method of contraception during treatment and for 2 weeks following discontinuation of treatment with dabrafenib or for 4 months following combination treatment with dabrafenib and trametinib. |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | limited to oncology and hematology  |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# TAGRISO

## Products Affected

- TAGRISO

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation of the presence of T790M mutation positive non-small cell lung cancer (NSCLC), documentation that the patient has progressed on or after EGFR TKI therapy, LVEF assessment by echocardiogram or MUGA scan before the initiation of therapy and confirmation this will be assessed at 3 month intervals while on treatment, confirmation that patients who have a history of or predisposition for QTc prolongation or those taking medications known to prolong the QTc interval will have periodic electrocardiogram and serum electrolyte monitoring, documentation that patients of reproductive potential have been advised to use highly effective contraception during Tagrisso therapy and for 6 weeks after the final dose for females, or for 4 months after the final dose for males |
| <b>Age Restrictions</b>             | 18 years of age or older  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology and Oncology  |
| <b>Coverage Duration</b>            | 3 months initially, then annually thereafter  |
| <b>Other Criteria</b>               | Continuation of approval requires submission of clinical benefit and absence of unacceptable toxicities and confirmation that required laboratory monitoring and cardiac imaging studies will be performed as clinically indicated. PA Applies to New Starts Only.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## TAKHZYRO (lanadelumab-flyo)

---

### Products Affected

- TAKHZYRO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D. |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use.  |
| <b>Age Restrictions</b>             | 12 years of age or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | 1 year   |
| <b>Other Criteria</b>               | PA applies to new starts only.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## TAVALISSE (fostamatinib)

### Products Affected

- TAVALISSE

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of platelet count, documentation patient had an insufficient response to prior treatment (including at least one of the following: corticosteroids, immunoglobulins, splenectomy, and/or a thrombopoietin receptor agonist). |
| <b>Age Restrictions</b>             | 18 years of age or older  |
| <b>Prescriber Restrictions</b>      | Restricted to hematology  |
| <b>Coverage Duration</b>            | Initially 12 weeks, then 1 year   |
| <b>Other Criteria</b>               | PA applies to all. Continuation of therapy requires submission of documentation of platelet count.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# TECENTRIQ

## Products Affected

- TECENTRIQ

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission of baseline LFTs (including AST, ALT, and total bilirubin) and submission of baseline thyroid function tests and confirmation these lab values will be monitored periodically while on therapy, confirmation patient will be monitored for signs and symptoms of pneumonitis, hepatitis, diarrhea or colitis, endocrinopathies, hypophysitis, meningitis or encephalitis, motor and sensory neuropathy, acute pancreatitis and infection, documentation that patient has had disease progression during or following platinum-containing chemotherapy, or has had disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing therapy |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to Hematology/Oncology Prescribers  |
| <b>Coverage Duration</b>            | One Year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: The provider administering the medication agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable or this clinical criteria. PA applies to new starts only.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Testosterone Replacement

## Products Affected

- ANDRODERM TRANSDERMAL PATCH 24 HOUR
- ANDROGEL
- ANDROGEL PUMP TRANSDERMAL GEL 20.25 MG/ACT (1.62%)
- FORTESTA
- NATESTO
- STRIANT
- TESTIM
- *testosterone transdermal gel 10 mg/act (2%), 12.5 mg/act (1%), 20.25 mg/1.25gm (1.62%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%), 50 mg/5gm (1%)*
- *testosterone transdermal solution*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, serum testosterone level, documentation that patient has been evaluated for the presence of prostate cancer prior to initiation of therapy |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## TIBSOVO (ivosidenib)

### Products Affected

- TIBSOVO

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.                          |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of FDA-approved test confirming presence of IDH1 mutation. |
| <b>Age Restrictions</b>             | 18 years of age or older  |
| <b>Prescriber Restrictions</b>      | Restricted to hematology and oncology   |
| <b>Coverage Duration</b>            | 1 year  |
| <b>Other Criteria</b>               | PA applies to new starts only.  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## TIGAN/ trimethobenzamide

### Products Affected

- TIGAN ORAL
- *trimethobenzamide hcl oral*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | 1)Patient has a current diagnosis of nausea and vomiting and 2)Patient must have tried and failed, or had an inadequate response to at least one other antiemetic medication such as Zofran or 3)Patient must have documentation of risk factors precluding them from therapy with alternative antiemetic therapy and 4)Documentation is available recording the provider is aware medication is considered a high risk medication for elderly patients according to the Centers for Medicare and Medicaid services and 5)Documentation is available explaining the benefits of the identified drug and how that benefit outweighs the potential risks to the patient. |
| <b>Age Restrictions</b>             | PA applies to age 65yo and older. PA is not required for under age 65yo.   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# TOBI PODHALER

---

## Products Affected

- TOBI PODHALER

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | 28 days   |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# TRACLEER

---

## Products Affected

- TRACLEER

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           | Pregnancy   |
| Required Medical Information | Diagnosis of Covered Use and Liver function tests                     |
| Age Restrictions             |   |
| Prescriber Restrictions      | Limited to Pulmonologists or Cardiologists                            |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Tricyclic Antidepressants

## Products Affected

- *amitriptyline hcl oral*
- *chlordiazepoxide-amitriptyline*
- *clomipramine hcl oral*
- *doxepin hcl oral*
- *imipramine hcl oral*
- *imipramine pamoate*
- *perphenazine-amitriptyline*
- *trimipramine maleate oral*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | The requested drug must be used to treat a medically accepted disease or condition including depression, headache treatment and prophylaxis ,neurpathic pain or other compendial use not otherwise excluded from Part D and patient must have tried and failed to tolerate or had an inadequate response to two preferred alternative therapies for labeled or off labeled indications including- For depression (applies to amitriptyline, imipramine, doxepin, and trimipramine): paroxetine, sertraline, venlafaxine, duloxetine, citalopram, escitalopram, fluoxetine, and trazodone,for headache treatment and prophylaxis (applies to amitriptyline) : propranolol, timolol, topiramate, valproic acid and divalproex, for anxiety (applies to doxepin): paroxetine, venlafaxine, duloxetine, and buspirone, for postherpetic neuralgia (applies to amitriptyline) or other neuropathic pain: gabapentin and pregabalin, for obsessive-compulsive disorder (applies to clomipramine): paroxetine, sertraline, fluoxetine, and fluvoxamine, for Irritable bowel syndrome (applies to amitriptyline, trimipramine and doxepin): laxatives or loperamide and Documentation is submitted confirming that the prescriber is aware the medication is considered a high risk medication for elderly patients according to the Centers for Medicare and Medicaid services and justification is submitted by the prescriber which explains what the benefit is and how the benefit outweighs the potential risks for the specific patient. |
| <b>Age Restrictions</b>             | PA applies to patients 65 YO or older   |
| <b>Prescriber Restrictions</b>      |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria       | Criteria Details               |
|-------------------|--------------------------------|
| Coverage Duration | One Year                       |
| Other Criteria    | PA applies to new starts only. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# TYKERB

## Products Affected

- TYKERB

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Documentation that Tykerb is being requested for the treatment of human epidermal growth factor receptor type 2 (HER2) overexpressing advanced or metastatic breast cancer in combination with capecitabine in patients who have received prior therapy including an anthracycline, a taxane, and trastuzumab or for the treatment of HER2 overexpressing hormone receptor?positive metastatic breast cancer in combination with letrozole in postmenopausal women where hormone therapy is indicted, submission of baseline ECG and LVEF and confirmation that evaluations of LVEF will continue during treatment, submission of baseline ALT ,AST and total bilirubin and confirmation liver functions tests will be monitored as clinically indicated during treatment, submission of baseline serum potassium and magnesium levels |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Oncologists/Hematologists   |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Tysabri

## Products Affected

- TYSABRI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Patients who have or have had PML, patients who have had a hypersensitivity reaction to Tysabri, requests for doses greater than 300mg every four weeks  |
| <b>Required Medical Information</b> | Diagnosis of covered use, documentation of previous therapies tried for MS or Crohn's disease and patient's response to these therapies,documentation that the patient is not receiving concurrent antineoplastic, immunosuppressant, or immunomodulating agents,forthe treatment of Crohn's disease- submission of CDAI score, confirmation that the medication is being prescribed, dispensed and administered in accordance with the TOUCH prescribing program to patients enrolled in and who meet all the requirements of the TOUCH precribing program,documentation that the healthcare setting and providers are prepared to manage infusion related reactions including life-threatening anaphylaxis |
| <b>Age Restrictions</b>             | 18YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to neurology or gastroenterology   |
| <b>Coverage Duration</b>            | For MS-One Year, for CD 12 weeks initially then if positive patient response-One Year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: A physician is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration. If these conditions are not satisfied this medication may be covered under Part B. PA applies to all.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Uptravi

## Products Affected

- UPTRAVI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.       |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use (pulmonary arterial hypertension (PAH, WHO Group I) |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to Pulmonologists and Cardiologists                                  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA Applies to All.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# VANDETANIB

---

## Products Affected

- CAPRELSA

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D  |
| Exclusion Criteria           | Patients with congenital long QT syndrome  |
| Required Medical Information | Diagnosis of covered use and lab values including: serum potassium, calcium, magnesium, bilirubin, and TSH, creatinine clearance, baseline ECG |
| Age Restrictions             | 18 YO or older   |
| Prescriber Restrictions      |  |
| Coverage Duration            | One Year   |
| Other Criteria               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# VECAMEYL

## Products Affected

- VECAMEYL

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | patients with mild, moderate, labile hypertension, patients with coronary insufficiency or history of recent myocardial infarction (MI), patients diagnosed with uremia, glaucoma or organic pyloric stenosis, patients receiving antibiotic and sulfonamide therapy               |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of patient weight, submission of serum creatinine and BUN values, submission of documentation confirming patient does not have any of the following- coronary insufficiency, history of recent MI, uremia, glaucoma, organic pyloric stenosis |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## VEMLIDY (TENOFIVIR ALAFENAMIDE)

### Products Affected

- VEMILIDY

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation patients will be tested for HIV infection prior to initiation of Vemlidy and that therapy will not be used in patients with HIV infection, confirmation baseline serum creatinine, serum phosphorous, estimated creatinine clearance, urine glucose, and urine protein will be assessed before initiation of therapy and during therapy as clinically appropriate |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | Prior Authorization is not required for Gastroenterology or Infectious Disease Specialists   |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA Applies to All.Vemlidy is not recommended in patients with estimated creatinine clearance below 15 mL per minute. Vemlidy is not recommended in patients with decompensated (Child-Pugh B or C) hepatic impairment  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Venclexta

## Products Affected

- VENCLEXTA
- VENCLEXTA STARTING PACK

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.  |
| Exclusion Criteria           | Concomitant use with strong CYP3A inhibitors during initiation and ramp-up period   |
| Required Medical Information | Diagnosis of covered medical use, documentation of 17p deletion, as detected by an FDA approved test who have received one prior therapy, documentation that tumor burden assessments will be performed prior to initiation and if necessary TLS prophylaxis may be administered based on results, submission of baseline CBC |
| Age Restrictions             | 18 YO or older  |
| Prescriber Restrictions      | Limited to Hematology and Oncology  |
| Coverage Duration            | One Year  |
| Other Criteria               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# Ventavis

## Products Affected

- VENTAVIS

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use,submission of baseline blood pressure reading,documentation that Ventavis will be inhaled using either the I-neb AAD system or the Prodose AAD system |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | limited to cardiology or pulmonology   |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | This medication is covered as a Part B benefit except for enrollees residing in a long-term care facility. PA applies to new starts only when covered as a Part D benefit.     |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Verzenio (abemaciclib)

### Products Affected

- VERZENIO

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.  |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use. Documentation that baseline WBC and LFT has been obtained and will be monitored routinely throughout therapy. Additionally, if being given to a female of reproductive potential, documentation of a negative pregnancy prior to initiation and that the patient has been counseled to use effective contraception during treatment and for at least three weeks after the last dose. |
| Age Restrictions             | 18 YO or older  |
| Prescriber Restrictions      | Limited to hematology/oncology  |
| Coverage Duration            | One year  |
| Other Criteria               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## VFEND

### Products Affected

- *voriconazole intravenous*
- *voriconazole oral*

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D  |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of Covered Use,patient weight  |
| Age Restrictions             |  |
| Prescriber Restrictions      |  |
| Coverage Duration            | 3 Months   |
| Other Criteria               | Infectious Disease Specialists are exempt from prior authorization. For intravenous preparation a B vs D determination must be made based on whether it is being administered via an infusion pump (B benefit) or not (part D benefit). PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# VIBERZI

## Products Affected

- VIBERZI

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Known or suspected biliary duct obstruction, or sphincter of Oddi disease or dysfunction, alcoholism, alcohol abuse, alcohol addiction, or patients who drink more than 3 alcoholic beverages/day, history of pancreatitis, structural diseases of pancreas, including known or suspected pancreatic duct obstruction, severe hepatic impairment (Child-Pugh Class C), severe constipation or sequelae from constipation, or known or suspected mechanical gastrointestinal obstruction |
| <b>Required Medical Information</b> | Diagnosis of covered use, documentation of history of cholecystectomy for the purposes of dose verification   |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA Applies to All   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## VOSEVI (sofosbuvir)

### Products Affected

- VOSEVI

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Patients on rifampin   |
| <b>Required Medical Information</b> | Diagnosis of covered use and laboratory confirmation of hepatitis C virus (HCV) as indicated consistent with current AASLD-IDSA guidance |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | 12 weeks   |
| <b>Other Criteria</b>               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# VOTRIENT

## Products Affected

- VOTRIENT

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## VPRIV

### Products Affected

- VPRIV

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, submission of patient's current weight, and documentation that administration personnel has been adequately training in cardiopulmonary resuscitative measures, and have ready access to emergency medical services due to risk of anaphylaxis reactions upon administration.   |
| <b>Age Restrictions</b>             | 4 years of age and older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: The provider administering the medication agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or infusion center for administration, if the medication is being administered in the enrollee's home confirmation that the home care service provider is adequately trained on how to prepare and administer the medication and is prepared to recognize and manage hypersensitivity reactions, including anaphylaxis. If these conditions are not satisfied this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable or this clinical criteria. PA applies to all. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# VRAYLAR

## Products Affected

- VRAYLAR

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D.  |
| Exclusion Criteria           | Known hypersensitivity to Vraylar   |
| Required Medical Information | Diagnosis of schizophrenia, or the treatment of manic or mixed episodes associated with bipolar I disorder, confirmation that patient's weight, fasting plasma glucose levels and lipid panel will be assessed at the initiation of therapy and periodically during long-term treatment, confirmation that patient heart rate and blood pressure will be monitored due to the potential for orthostatic hypotension |
| Age Restrictions             | 18 YO and older   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# XALKORI

---

## Products Affected

- XALKORI

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D         |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use, Lab values including ALT, AST, total bilirubin, CBC |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA for new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# XENAZINE

## Products Affected

- AUSTEDO
- *tetrabenazine*

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of covered use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | One Year  |
| Other Criteria               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## XERMELO (telotristat)

### Products Affected

- XERMELO

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use and documentation that patient has previously been on at least 12 weeks of prior somatostatin analog therapy and that baseline GGT has been drawn and will be monitored throughout therapy. |
| <b>Age Restrictions</b>             | 18YO and older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | 12 weeks   |
| <b>Other Criteria</b>               | Continuation of therapy requires that symptoms have stabilized or improved and that the patient has not experienced episodes of severe constipation.   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Xolair

## Products Affected

- XOLAIR

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | self-administration by the patient, based on the dosing table in the prescribing information patients who serum IgE level and body weight place them in the do not dose category  |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation patient will receive treatment in a doctor's office or clinic and be observed for an appropriate amount of time after each treatment, documentation that the healthcare setting and providers are prepared to manage life-threatening anaphylaxis and for the treatment of asthma- submission of patient current body weight and pre-treatment serum IgE level, submission of pulmonary function test results including FEV1, submission of positive skin test result or demonstrated in-vitro reactivity (RAST test) to a perennial aeroallergen, submission of documentation that patients symptoms are poorly controlled with inhaled corticosteroids, requery of inhaled short-acting beta2-agonist therapy, submission of frequency of daily and nighttime symptoms and exacerbations, effect of exacerbations on activity. For the treatment of chronic idiopathic urticaria-submission of documentation that the patient continues to experience severe itching and hives despite the use of an H1 antihistamine at an approved dose. |
| <b>Age Restrictions</b>             | 6 YO or older   |
| <b>Prescriber Restrictions</b>      | Limited to allergy, pulmonology, dermatology or immunology  |
| <b>Coverage Duration</b>            | one year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details   |
|-----------------------|--|
| <b>Other Criteria</b> | Continuation of therapy requests require objective documentation from the prescriber that the patient's symptoms have improved.If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied:A a physician is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or clinic for administration If these conditions are not satisfied this medication may be covered under Part B.PA applies to all |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# XTANDI

## Products Affected

- XTANDI

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | diagnosis of covered use  |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to oncologists/hematologists                                  |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# XURIDEN

## Products Affected

- XURIDEN

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of hereditary orotic aciduria, submission of current weight, submission of baseline CBC including neutrophil count and mean corpuscular volume, submission of baseline urine orotic acid level |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | Continuation of approval requires submission of updated weight, CBC including neutrophil count and mean corpuscular volume and urine orotic acid level   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# Yondelis

## Products Affected

- YONDELIS

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Patients with a known hypersensitivity to trabectedin   |
| <b>Required Medical Information</b> | Diagnosis of covered use,confirmation patient has had a prior anthracycline containing chemotherapy regimen,confirmation patient will receive premedication with dexamethasone prior to each Yondelis dose, submission of patient height and current weight (weight obtained within the previous month to calculate BSA for dose verification), confirmation that patient's with moderate hepatic impairment(defined as bilirubin levels 1.5 to 3 times the UNL, and AST and ALT less than 8 times the ULN)dosage will be adjusted according to the PI receommendations, that patient's with severe hepatic impairment (defined as bilirubin levels above 3-10 times the ULN, and any AST and ALT) will not receive Yondelis, confirmation the following baseline laboratory values have been obtained neutrophil count, CPK levels, AST, ALT, bilirubin levels, LVEF assessment by either MUGA scan or ECG and will be monitored while patient is on therapy and treatment interrupted, dosage reduced or drug discontinued based on the severity of the abnormality per the recommendations in the PI, confirmation female patients of reproductive potential have been advised to use effective contraception during and for 2 months after the last Yondelis dose and male patients with a female sexual partner of reproductive potential have been advised to use effective contraception during and for 5 months after the last Yondelis dose. |
| <b>Age Restrictions</b>             | 18 years of age and older   |
| <b>Prescriber Restrictions</b>      | Limited to oncology and hematology providers only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



| PA Criteria       | Criteria Details  |
|-------------------|---|
| Coverage Duration | Indefinite  |
| Other Criteria    | If the medication is being obtained at a retail pharmacy or furnished directly to the patient, it may be covered under Part D provided the following conditions are satisfied:A healthcare professional is administering the medication and he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office, infusion center or home care provider for administration If these conditions are not satisfied this medication may be covered under Part B. PA applies to new starts only. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ZAVESCA

## Products Affected

- *miglustat*
- ZAVESCA

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D  |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of Covered Use and documentation that other treatment options have failed including one of the following Imiglucerase or Velaglucerase Alfa. |
| Age Restrictions             | 18 YO or older   |
| Prescriber Restrictions      |  |
| Coverage Duration            | One Year   |
| Other Criteria               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## ZEJULA (niraparnib)

### Products Affected

- ZEJULA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D. It is indicated for maintenance treatment of women who have responded at least partially to platinum-based chemotherapy for recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One year  |
| <b>Other Criteria</b>               |   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ZELBORAF

---

## Products Affected

- ZELBORAF

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           |   |
| <b>Required Medical Information</b> | Diagnosis of covered use, lab values including ECG, serum potassium, magnesium and calcium levels, ALT and bilirubin, dermatological exam |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to new starts only   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ZERBAXA

## Products Affected

- ZERBAXA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.<br>All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           | Known serious hypersensitivity to ceftolozane/tazobactam, piperacillin/tazobactam, or other members of the beta-lactam class   |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, submission of patient current weight and serum creatinine level for the purposes of calculating creatinine clearance and dosage verification, confirmation patient will receive concurrent metronidazole therapy when used for the treatment of complicated intra-abdominal infections |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | Maximum of 14 days based on severity and site of infection   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office for administration. If these conditions are not satisfied or this medication is being administered in the patient's home via an external infusion pump this medication may be covered under Part B in accordance with the corresponding NCD/LCD if applicable. If this medication is being administered in the patients' home via IV drip it is covered as a Part D benefit. 14 days of therapy may be authorized for the treatment of complicated intra-abdominal infections. 7 days of therapy may be authorized for the treatment of urinary tract infections including pyelonephritis.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## ZINBRYTA (daclizumab)

### Products Affected

- ZINBRYTA

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | pre-existing hepatic disease or impairment, including ALT or AST at least 2 times the ULN, history of autoimmune hepatitis or other autoimmune condition involving the liver, history of hypersensitivity to daclizumab or any other component of the formulation   |
| <b>Required Medical Information</b> | Diagnosis of covered medical use, confirmation patient is diagnosed with a relapsing form of MS and has tried and failed to achieve an adequate response to at least two drugs indicated for the treatment of MS, submission of baseline liver function tests including ALT, AST, and total bilirubin levels less than 2 times the ULN and confirmation these lab values will be assessed before each monthly injection and for 6 months after the last dose of Zinbryta is administered, confirmation high risk patients (tuberculosis endemic areas) will be evaluated for TB infection prior to initiating treatment and for those testing positive tuberculosis will be treated by standard medical practice prior to initiating therapy, confirmation patient has been screened for the presence of Hepatitis B and c and confirmation patient has been counseled about and will be monitored for developing depression and/or suicidal ideation |
| <b>Age Restrictions</b>             | 17 YO or older  |
| <b>Prescriber Restrictions</b>      | Limited to neurology  |
| <b>Coverage Duration</b>            | One Year  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | PA applies to all. Continuation of approval requires submission of objective clinical documentation of a positive patient therapeutic response and medication tolerability, submission of updated ALT, AST and total bilirubin (obtained within the previous 30 days) less than 2 times the ULN and documented compliance with all REMs program requirements. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# ZOLPIDEM

## Products Affected

- AMBIEN
- AMBIEN CR
- *zolpidem tartrate er*
- *zolpidem tartrate oral*

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use and documentation that the provider is aware of the associated risks, specifically: cognitive impairment, delirium, unsteady gait, syncope, falls, fractures and motor vehicle accidents, and confirmation that the prescriber is aware the medication is considered high risk for elderly patients by the Centers for Medicare and Medicaid services and submission of justification by the prescriber which explains how that benefits of the drug outweighs the potential risks for the specific patient, and confirmation that at least two of: trazadone, Rozerem, and/or Silenor have been tried and were ineffective or intolerable. |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One year   |
| <b>Other Criteria</b>               |  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ZONTIVITY

## Products Affected

- ZONTIVITY

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.  |
| <b>Exclusion Criteria</b>           | Do not use ZONTIVITY in patients with a history of stroke,transient ischemic attack (TIA), intracranial hemorrhage (ICH) or active pathological bleeding. |
| <b>Required Medical Information</b> | Diagnosis of Covered Use, documentation of concurrent use with aspirin and/or clopidogrel   |
| <b>Age Restrictions</b>             | 18 YO or older  |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | One Year  |
| <b>Other Criteria</b>               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Zorbtive

---

### Products Affected

- ZORBTIVE

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use  |
| Age Restrictions             |   |
| Prescriber Restrictions      |   |
| Coverage Duration            | Four weeks  |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## ZURAMPIC (lesinurad)

### Products Affected

- ZURAMPIC

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D.   |
| <b>Exclusion Criteria</b>           | Severe renal impairment, end stage renal disease, kidney transplant recipients, or patient is receiving dialysis, tumor lysis syndrome or Lesch-Nyhan syndrome   |
| <b>Required Medical Information</b> | Diagnosis of covered use, confirmation that patient's hyperurecemia is symptomatic, submission of patient weight and serum creatinine level obtained within the previous month for the purposes of estimated calculating creatinine clearance and confirmation that patient's eCrCl will continued to be monitored periodically while the patient is on therapy, confirmation therapy will not be initiated if eCrCl is less than 45ml/min and ongoing therapy will be discontinued if eCrCl consistently is under 45ml/min, submission of patient's serum uric acid target goal and serum uric acid level obtained within the previous three months documenting patient has not been able to achieve target serum uric acid levels with a xanthine oxidase inhibitor alone,documentation that Zurampic will be used in conjunction with a xanthine oxidase inhibitor and that patient has been instructed on the importance of staying well hydrated defined as consuming of 68oz of liquid per day,confirmation patient does not have severe hepatic impairment as therapy is not recommended in this patient population |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      |  |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA Applies to All  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## ZYFLO

### Products Affected

- *zileuton er*
- ZYFLO

| PA Criteria                  | Criteria Details  |
|------------------------------|---|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D   |
| Exclusion Criteria           |   |
| Required Medical Information | Diagnosis of Covered Use and Lab values including: ALT levels and PFT's |
| Age Restrictions             | 12 YO   |
| Prescriber Restrictions      |   |
| Coverage Duration            | one year  |
| Other Criteria               | PA applies to all   |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ZYKADIA

## Products Affected

- ZYKADIA

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D  |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of covered use, submission of baseline ALT, AST and total bilirubin obtained within the previous three months and confirmation liver function tests will be monitored monthly, submission of baseline ECG, heart rate and serum electrolyte levels obtained within the previous three months, submission of baseline serum glucose level obtained within the previous three months |
| <b>Age Restrictions</b>             | 18 YO or older   |
| <b>Prescriber Restrictions</b>      | limited to oncology and hematology   |
| <b>Coverage Duration</b>            | One Year   |
| <b>Other Criteria</b>               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ZYTIGA

## Products Affected

- ZYTIGA

| PA Criteria                  | Criteria Details   |
|------------------------------|--|
| Covered Uses                 | All medically accepted indications not otherwise excluded from Part D  |
| Exclusion Criteria           |  |
| Required Medical Information | Diagnosis of covered use, documentation of other treatments tried, confirmation patient will receive concurrent prednisone, baseline ALT, AST, bilirubin, and serum potassium level, baseline LVEF |
| Age Restrictions             | 18 YO or older   |
| Prescriber Restrictions      |  |
| Coverage Duration            | One Year   |
| Other Criteria               | PA applies to new starts only  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

# ZYVOX

## Products Affected

- *linezolid oral*
- ZYVOX ORAL

| PA Criteria                         | Criteria Details   |
|-------------------------------------|--|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D                              |
| <b>Exclusion Criteria</b>           |  |
| <b>Required Medical Information</b> | Diagnosis of Covered Use and Culture   |
| <b>Age Restrictions</b>             |  |
| <b>Prescriber Restrictions</b>      | Limited to Infectious Disease Specialist   |
| <b>Coverage Duration</b>            | Vancomycin-resistant E. faecium infections - 28 days, all other FDA approved indications - 14 days |
| <b>Other Criteria</b>               | PA applies to all  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.



# Zyvox injection

## Products Affected

- *linezolid intravenous solution 600 mg/300ml*

| PA Criteria                         | Criteria Details  |
|-------------------------------------|---|
| <b>Covered Uses</b>                 | All medically accepted indications not otherwise excluded from Part D   |
| <b>Exclusion Criteria</b>           | Known hypersensitivity to linezolid, patients taking any medicinal product that inhibits monoamine oxidases A or B (eg, isocarboxazid, phenelzine) or within 2 weeks of taking any such medicinal product, uncontrolled hypertension, pheochromocytoma, thyrotoxicosis, and/or patients taking any of the following types of medications- directly and indirectly acting sympathomimetic agents (eg, pseudoephedrine), vasopressive agents (eg, epinephrine, norepinephrine), or dopaminergic agents (eg, dopamine, dobutamine), unless patient is monitored for potential increase in blood pressure, carcinoid syndrome and/or patients taking any of the following medications- serotonin reuptake inhibitors, tricyclic antidepressants, serotonin 5-HT <sub>1</sub> receptor agonists (triptans), meperidine, or buspirone, unless carefully observed for signs and/or symptoms of serotonin syndrome. |
| <b>Required Medical Information</b> | Diagnosis of covered use confirmed by submission of culture and sensitivity results, submission of CBC  |
| <b>Age Restrictions</b>             |   |
| <b>Prescriber Restrictions</b>      |   |
| <b>Coverage Duration</b>            | Vancomycin-resistant E. faecium infections - 28 days, all other FDA approved indications - 14 days  |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

| PA Criteria           | Criteria Details  |
|-----------------------|---|
| <b>Other Criteria</b> | <p>If the medication is being obtained at a retail pharmacy, it may be covered under Part D provided the following conditions are satisfied: If a physician or healthcare provider is administering the medication, he/she agrees to accept brown bagging of the medication and understands that the enrollee will obtain the medication from a pharmacy and have it in their possession until the enrollee delivers the medication to the physician office or clinic for administration, if the medication is being self-administered documentation is provided that the enrollee has been fully trained on how to prepare the injection and to administer the medication safely and effectively if applicable. If these conditions are not satisfied this medication may be covered under Part B.</p> |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

You can find information on what the symbols and abbreviations on this table mean by going to page VI.

## Index

|  |     |  |     |
|--|-----|--|-----|
| ABILIFY MYCITE ORAL TABLET 10 MG, 15 MG, 2 MG, 20 MG, 30 MG, 5 MG..... | 2   | ARANESP (ALBUMIN FREE) INJECTION SOLUTION 100 MCG/ML, 200 MCG/ML, 25 MCG/ML, 300 MCG/ML, 40 MCG/ML, 60 MCG/ML..... | 81  |
| ABRAXANE.....  | 114 | ARANESP (ALBUMIN FREE) INJECTION SOLUTION PREFILLED SYRINGE.....   | 81  |
| ABSTRAL.....   | 89  | ARCALYST.....  | 20  |
| <i>acitretin</i> .....   | 192 | ARRANON.....   | 114 |
| ACTIMMUNE.....   | 212 | ARZERRA INTRAVENOUS CONCENTRATE 100 MG/5ML.....  | 114 |
| ACTIVELLA.....   | 83  | <i>ascomp-codeine</i> .....  | 36  |
| ADAGEN.....  | 4   | AUSTEDO.....   | 265 |
| ADCIRCA.....   | 5   | AVASTIN.....   | 114 |
| ADEMPAS.....   | 6   | <i>azacitidine</i> .....   | 114 |
| <i>adriamycin intravenous solution</i> .....                           | 114 | BAVENCIO.....  | 21  |
| ADRUCIL INTRAVENOUS SOLUTION 500 MG/10ML.....                          | 7   | BELEODAQ.....  | 22  |
| AFINITOR.....  | 8   | BENLYSTA.....  | 23  |
| AFINITOR DISPERZ.....  | 8   | BENZNIDAZOLE.....  | 25  |
| AIMOVIG.....   | 9   | <i>benztropine mesylate oral</i> .....   | 71  |
| AIMOVIG 140 DOSE.....  | 9   | BERINERT.....  | 26  |
| AKYNZEO ORAL.....  | 10  | BEVYXXA.....   | 27  |
| ALECENSA.....  | 12  | BICNU.....   | 114 |
| ALIMTA.....  | 114 | BIVIGAM.....   | 111 |
| ALIQOPA.....   | 14  | <i>bleomycin sulfate injection solution reconstituted 30 unit</i> .....  | 114 |
| ALKERAN INTRAVENOUS.....   | 114 | BONIVA INTRAVENOUS.....  | 30  |
| ALORA.....   | 83  | <i>bortezomib</i> .....  | 114 |
| ALUNBRIG.....  | 16  | BOSULIF.....   | 32  |
| <i>amabelz</i> .....   | 83  | BOTOX.....   | 33  |
| AMBIEN.....  | 280 | BRAFTOVI.....  | 34  |
| AMBIEN CR.....   | 280 | BRIVIACT.....  | 35  |
| <i>amitriptyline hcl oral</i> .....                                    | 246 | BUPAP ORAL TABLET 50-300 MG.....   | 36  |
| AMPYRA.....  | 17  | <i>busulfan</i> .....  | 114 |
| AMRIX.....   | 218 | BUSULFEX.....  | 114 |
| ANADROL-50.....  | 18  | <i>butalbital-acetaminophen oral tablet 50-325 mg</i> .....  | 36  |
| ANDRODERM TRANSDERMAL PATCH 24 HOUR.....                               | 241 | <i>butalbital-apap-caff-cod</i> .....  | 36  |
| ANDROGEL.....  | 241 | <i>butalbital-apap-caffeine oral capsule</i> .....   | 36  |
| ANDROGEL PUMP TRANSDERMAL GEL 20.25 MG/ACT (1.62%).....                | 241 | <i>butalbital-apap-caffeine oral tablet 50-325-40 mg</i> .....   | 36  |
| ANDROID.....   | 153 | <i>butalbital-asa-caff-codeine</i> .....   | 36  |
| ANGELIQ.....   | 83  | <i>butalbital-aspirin-caffeine oral capsule</i> .....  | 36  |
| APOKYN SUBCUTANEOUS SOLUTION CARTRIDGE.....                            | 192 | BUTISOL SODIUM ORAL TABLET 30 MG.....  | 71  |
| ARALAST NP INTRAVENOUS SOLUTION RECONSTITUTED 1000 MG, 500 MG.....     | 198 |  |     |

|  |     |  |     |
|--|-----|--|-----|
| CABOMETYX.....                                       | 37  | <i>cytarabine (pf) injection solution 100</i>      |     |
| CALQUENCE.....                                       | 38  | <i>mg/ml.....</i>                                  | 114 |
| CAMPTOSAR INTRAVENOUS SOLUTION                       |     | <i>cytarabine injection solution.....</i>          | 114 |
| 100 MG/5ML.....                                      | 114 | CYTOVENE.....                                      | 58  |
| CAPRELSA.....  | 252 | <i>dacarbazine intravenous solution</i>            |     |
| CARBAGLU.....  | 39  | <i>reconstituted 200 mg.....</i>                   | 114 |
| <i>carbinoxamine maleate oral solution.....</i>      | 211 | DACOGEN.....                                       | 114 |
| <i>carbinoxamine maleate oral tablet 4 mg...211</i>  |     | <i>dactinomycin.....</i>                           | 114 |
| CARIMUNE NF INTRAVENOUS SOLUTION                     |     | <i>dalfampridine er.....</i>                       | 17  |
| RECONSTITUTED 12 GM, 6 GM.....                       | 111 | DARZALEX.....                                      | 59  |
| <i>carisoprodol oral.....</i>                        | 71  | <i>daunorubicin hcl intravenous injectable ...</i> | 114 |
| CERDELGA.....  | 40  | <i>daunorubicin hcl intravenous solution.....</i>  | 114 |
| CEREZYME INTRAVENOUS SOLUTION                        |     | <i>decitabine.....</i>                             | 114 |
| RECONSTITUTED 400 UNIT.....                          | 41  | DEPO-TESTOSTERONE INTRAMUSCULAR                    |     |
| CESAMET.....   | 43  | SOLUTION.....                                      | 117 |
| CHENODAL.....  | 44  | DESOXYN.....                                       | 151 |
| <i>chlordiazepoxide-amitriptyline.....</i>           | 246 | <i>dexrazoxane intravenous solution</i>            |     |
| <i>chlorpropamide.....</i>                           | 71  | <i>reconstituted 250 mg.....</i>                   | 114 |
| <i>chlorzoxazone oral tablet 500 mg.....</i>         | 218 | <i>diclofenac sodium transdermal gel 3 %.....</i>  | 219 |
| CHOLBAM.....   | 45  | DIFICID.....                                       | 64  |
| <i>chorionic gonadotropin intramuscular.....</i>     | 46  | <i>digitek oral tablet 250 mcg.....</i>            | 65  |
| CINQAIR.....   | 47  | <i>digox oral tablet 250 mcg.....</i>              | 65  |
| CINRYZE.....   | 49  | <i>digoxin injection.....</i>                      | 65  |
| <i>cisplatin intravenous solution 100</i>            |     | <i>digoxin oral solution.....</i>                  | 65  |
| <i>mg/100ml, 50 mg/50ml.....</i>                     | 114 | <i>digoxin oral tablet 250 mcg.....</i>            | 65  |
| <i>cladribine intravenous solution 10</i>            |     | <i>diphenhydramine hcl oral elixir.....</i>        | 211 |
| <i>mg/10ml.....</i>                                  | 114 | <i>dipyridamole oral.....</i>                      | 71  |
| <i>clemastine fumarate oral tablet 2.68 mg...211</i> |     | <i>disopyramide phosphate oral.....</i>            | 71  |
| CLIMARA PRO.....                                     | 83  | DIVIGEL TRANSDERMAL GEL 0.5                        |     |
| <i>clofarabine.....</i>                              | 114 | MG/0.5GM, 1 MG/GM.....                             | 83  |
| <i>clomipramine hcl oral.....</i>                    | 246 | <i>docetaxel intravenous concentrate 80</i>        |     |
| COMBIPATCH.....                                      | 83  | <i>mg/4ml.....</i>                                 | 114 |
| COMETRIQ (100 MG DAILY DOSE).....                    | 50  | <i>docetaxel intravenous solution 160</i>          |     |
| COMETRIQ (140 MG DAILY DOSE).....                    | 50  | <i>mg/16ml, 80 mg/8ml.....</i>                     | 114 |
| COMETRIQ (60 MG DAILY DOSE).....                     | 50  | DOCETAXEL INTRAVENOUS SOLUTION 20                  |     |
| CORLANOR.....  | 51  | MG/2ML.....  | 114 |
| COTELIC.....   | 52  | DOPTELET.....                                      | 66  |
| CRINONE.....   | 192 | <i>doxepin hcl oral.....</i>                       | 246 |
| CUPRIMINE ORAL CAPSULE 250 MG.....                   | 54  | DOXIL.....   | 114 |
| <i>cyclobenzaprine hcl oral.....</i>                 | 218 | <i>doxorubicin hcl intravenous solution.....</i>   | 114 |
| <i>cyproheptadine hcl oral.....</i>                  | 71  | <i>doxorubicin hcl liposomal.....</i>              | 114 |
| CYRAMZA.....   | 55  | DUAVEE.....  | 83  |
| CYSTARAN.....  | 57  | DUOPA ENTERAL.....                                 | 67  |

|  |  |     |
|--|--|-----|
| DUPIXENT SUBCUTANEOUS SOLUTION                       | FERRIPROX.....                                 | 90  |
| PREFILLED SYRINGE 300 MG/2ML.....                    | FEXMID.....                                    | 218 |
| DYSPORT.....   | FIORICET ORAL CAPSULE.....                     | 36  |
| EGRIFTA SUBCUTANEOUS SOLUTION                        | FIORICET/CODEINE ORAL CAPSULE 50-300-          |     |
| RECONSTITUTED 1 MG.....                              | 40-30 MG.....                                  | 36  |
| ELESTRIN.....  | FIORINAL.....                                  | 36  |
| ELIGARD.....   | FIORINAL/CODEINE #3.....                       | 36  |
| ELITEK.....  | FIRAZYR.....                                   | 91  |
| ELLEENCE INTRAVENOUS SOLUTION 200                    | FIRMAGON.....                                  | 92  |
| MG/100ML.....  | FLEBOGAMMA DIF.....                            | 111 |
| <i>emflaza</i> .....                                 | FLECTOR.....                                   | 93  |
| EMPLICITI.....                                       | <i>fludarabine phosphate intravenous</i>       |     |
| EMSAM.....   | <i>solution reconstituted</i> .....            | 114 |
| EPCLUSA.....   | <i>fluorouracil intravenous solution 2.5</i>   |     |
| EPIDIOLEX.....                                       | <i>gm/50ml, 5 gm/100ml</i> .....               | 7   |
| <i>epirubicin hcl intravenous solution 200</i>       | FOLOTYN INTRAVENOUS SOLUTION 40                |     |
| <i>mg/100ml, 50 mg/25ml</i> .....                    | MG/2ML.....                                    | 114 |
| EPOGEN INJECTION SOLUTION 10000                      | FORTEO SUBCUTANEOUS SOLUTION 600               |     |
| UNIT/ML, 2000 UNIT/ML, 20000 UNIT/ML..               | MCG/2.4ML.....                                 | 94  |
| EPOGEN INJECTION SOLUTION 3000                       | FORTESTA.....                                  | 241 |
| UNIT/ML, 4000 UNIT/ML.....                           | <i>fyavolv</i> .....                           | 83  |
| ERBITUX.....   | GALAFOLD.....                                  | 95  |
| ERIVEDGE.....  | GAMASTAN S/D INTRAMUSCULAR                     |     |
| ERLEADA.....   | INJECTABLE.....                                | 123 |
| ERWINAZE INJECTION.....                              | GAMMAGARD.....                                 | 111 |
| ESBRIET.....   | GAMMAGARD S/D LESS IGA.....                    | 111 |
| ESGIC ORAL TABLET.....                               | GAMMAKED.....                                  | 111 |
| ESTRACE ORAL.....                                    | GAMMAPLEX INTRAVENOUS SOLUTION 10              |     |
| <i>estradiol oral</i> .....                          | GM/100ML, 10 GM/200ML, 20                      |     |
| <i>estradiol transdermal</i> .....                   | GM/200ML, 20 GM/400ML, 5 GM/100ML,             |     |
| <i>estradiol-norethindrone acet</i> .....            | 5 GM/50ML.....                                 | 111 |
| <i>estropipate oral tablet 0.75 mg, 1.5 mg</i> ..... | GAMUNEX-C.....                                 | 111 |
| EUCRISA.....   | <i>ganciclovir sodium intravenous solution</i> |     |
| EVAMIST.....   | <i>reconstituted</i> .....                     | 58  |
| EXJADE.....  | GATTEX.....                                    | 96  |
| FABIOR.....  | <i>gemcitabine hcl intravenous solution</i>    |     |
| FABRAZYME.....                                       | <i>reconstituted 1 gm</i> .....                | 114 |
| FARYDAK.....   | GEMZAR INTRAVENOUS SOLUTION                    |     |
| FASENRA.....   | RECONSTITUTED 1 GM.....                        | 114 |
| FASLODEX INTRAMUSCULAR SOLUTION                      | GENOTROPIN.....                                | 101 |
| 250 MG/5ML.....                                      | GENOTROPIN MINIQUEEK.....                      | 101 |
| <i>fentanyl citrate buccal</i> .....                 | GILOTRIF.....                                  | 97  |
| FENTORA BUCCAL TABLET 100 MCG, 200                   | GLASSIA.....                                   | 198 |
| MCG, 400 MCG, 600 MCG, 800 MCG.....                  | GLEEVEC.....                                   | 98  |

|  |     |  |     |
|--|-----|--|-----|
| GOCOVRI.....                                     | 99  | IRESSA.....                                    | 122 |
| GRASTEK.....                                     | 100 | <i>irinotecan hcl intravenous solution 100</i> |     |
| <i>guanfacine hcl er</i> .....                   | 71  | <i>mg/5ml</i> .....                            | 114 |
| <i>guanfacine hcl oral</i> .....                 | 71  | ISTODAX (OVERFILL).....                        | 114 |
| HAEGARDA.....                                    | 102 | <i>itraconazole oral</i> .....                 | 19  |
| HALAVEN.....                                     | 114 | IXEMPRA KIT INTRAVENOUS SOLUTION               |     |
| HARVONI.....                                     | 103 | RECONSTITUTED 45 MG.....                       | 114 |
| HEMANGEOL.....                                   | 104 | JADENU.....                                    | 60  |
| HERCEPTIN INTRAVENOUS SOLUTION                   |     | JADENU SPRINKLE.....                           | 60  |
| RECONSTITUTED 150 MG, 440 MG.....                | 114 | JAKAFI.....                                    | 125 |
| HETLIOZ.....                                     | 105 | JEVTANA.....                                   | 114 |
| HP ACTHAR.....                                   | 3   | JINTELI.....                                   | 83  |
| HUMATROPE.....                                   | 101 | JUBLIA.....                                    | 126 |
| <i>hydroxyzine hcl oral tablet</i> .....         | 106 | JUXTAPID.....                                  | 127 |
| <i>hydroxyzine pamoate oral</i> .....            | 106 | JYNARQUE.....                                  | 128 |
| <i>ibandronate sodium intravenous solution 3</i> |     | KADCYLA.....                                   | 114 |
| <i>mg/3ml</i> .....                              | 30  | KALYDECO.....                                  | 129 |
| IBRANCE.....                                     | 107 | KANUMA.....                                    | 130 |
| ICLUSIG.....                                     | 192 | KERYDIN.....                                   | 126 |
| IDAMYCIN PFS INTRAVENOUS SOLUTION                |     | <i>ketoconazole oral</i> .....                 | 131 |
| 20 MG/20ML.....                                  | 114 | <i>ketorolac tromethamine oral</i> .....       | 71  |
| <i>idarubicin hcl intravenous solution 10</i>    |     | KEYEYIS.....                                   | 132 |
| <i>mg/10ml</i> .....                             | 114 | KEYTRUDA.....                                  | 133 |
| IDHIFA.....                                      | 74  | KISQALI 200 DOSE.....                          | 134 |
| IFEX INTRAVENOUS SOLUTION                        |     | KISQALI 400 DOSE.....                          | 134 |
| RECONSTITUTED 1 GM.....                          | 114 | KISQALI 600 DOSE.....                          | 134 |
| <i>ifosfamide intravenous solution</i>           |     | KISQALI FEMARA 200 DOSE.....                   | 134 |
| <i>reconstituted 1 gm</i> .....                  | 114 | KISQALI FEMARA 400 DOSE.....                   | 134 |
| ILARIS SUBCUTANEOUS SOLUTION.....                | 108 | KISQALI FEMARA 600 DOSE.....                   | 134 |
| <i>imatinib mesylate</i> .....                   | 98  | KORLYM.....                                    | 135 |
| IMBRUVICA.....                                   | 110 | KUVAN.....                                     | 136 |
| IMFINZI.....                                     | 69  | KYNAMRO SUBCUTANEOUS SOLUTION                  |     |
| <i>imipramine hcl oral</i> .....                 | 246 | PREFILLED SYRINGE.....                         | 137 |
| <i>imipramine pamoate</i> .....                  | 246 | KYPROLIS.....                                  | 138 |
| <i>imiquimod external</i> .....                  | 11  | LANOXIN INJECTION SOLUTION 0.25                |     |
| INCRELEX.....                                    | 112 | MG/ML.....                                     | 65  |
| INDOCIN ORAL.....                                | 71  | LANOXIN ORAL TABLET 187.5 MCG, 250             |     |
| <i>indomethacin er</i> .....                     | 71  | MCG.....                                       | 65  |
| <i>indomethacin oral</i> .....                   | 71  | LARTRUVO.....                                  | 140 |
| INGREZZA.....                                    | 113 | LAZANDA.....                                   | 89  |
| INLYTA.....                                      | 118 | LENVIMA 10 MG DAILY DOSE.....                  | 142 |
| INTRON A.....                                    | 119 | LENVIMA 12 MG DAILY DOSE.....                  | 142 |
| INTUNIV.....                                     | 71  | LENVIMA 14 MG DAILY DOSE.....                  | 142 |
| INVEGA TRINZA.....                               | 121 | LENVIMA 18 MG DAILY DOSE.....                  | 142 |

|   |     |   |          |
|---|-----|---|----------|
| LENVIMA 20 MG DAILY DOSE.....             | 142 | <i>mimvey lo</i> .....                          | 83       |
| LENVIMA 24 MG DAILY DOSE.....             | 142 | MINIVELLE.....                                  | 83       |
| LENVIMA 4 MG DAILY DOSE.....              | 142 | MIRVASO.....                                    | 155      |
| LENVIMA 8 MG DAILY DOSE.....              | 142 | <i>mitomycin intravenous</i> .....              | 114, 192 |
| LETAIRIS.....                             | 143 | <i>mitoxantrone hcl intravenous concentrate</i> |          |
| LEUKINE INTRAVENOUS.....                  | 144 | <i>25 mg/12.5ml</i> .....                       | 114      |
| <i>leuprolide acetate injection</i> ..... | 212 | <i>modafinil</i> .....                          | 197      |
| <i>lidocaine external patch 5 %</i> ..... | 145 | MODERIBA 1200 DOSE PACK.....                    | 188      |
| LIDODERM.....                             | 145 | MODERIBA 800 DOSE PACK.....                     | 188      |
| <i>linezolid intravenous solution 600</i> |     | MODERIBA ORAL TABLET 200 MG.....                | 188      |
| <i>mg/300ml</i> .....                     | 288 | MOZOBIL.....                                    | 156      |
| <i>linezolid oral</i> .....               | 287 | MULPLETA.....                                   | 157      |
| LONSURF.....                              | 146 | MUSTARGEN.....                                  | 114      |
| <i>lopreeza</i> .....                     | 83  | MYALEPT.....                                    | 158      |
| LUCEMYRA.....                             | 147 | MYLOTARG INTRAVENOUS SOLUTION                   |          |
| LUMIZYME.....                             | 13  | RECONSTITUTED 4.5 MG.....                       | 159      |
| LUPRON DEPOT (1-MONTH).....               | 212 | MYTESI.....                                     | 161      |
| LUPRON DEPOT (3-MONTH).....               | 212 | NAGLAZYME.....                                  | 162      |
| LUPRON DEPOT (4-MONTH).....               | 212 | NAMZARIC.....                                   | 163      |
| LUPRON DEPOT (6-MONTH).....               | 212 | NATESTO.....                                    | 241      |
| LUPRON DEPOT-PED (1-MONTH)                |     | NATPARA.....                                    | 164      |
| INTRAMUSCULAR KIT 11.25 MG, 15 MG...      | 212 | NERLYNX.....                                    | 165      |
| LUPRON DEPOT-PED (3-MONTH)                |     | NEULASTA ONPRO.....                             | 166      |
| INTRAMUSCULAR KIT 30 MG (PED).....        | 212 | NEULASTA SUBCUTANEOUS SOLUTION                  |          |
| LYNPARZA.....                             | 148 | PREFILLED SYRINGE.....                          | 166      |
| MAVYRET.....                              | 149 | NEXAVAR.....                                    | 167      |
| MEKINIST.....                             | 150 | <i>nifedipine oral</i> .....                    | 71       |
| MEKTOVI.....                              | 34  | NINLARO.....                                    | 168      |
| <i>melphalan hcl</i> .....                | 114 | NIPENT.....                                     | 114      |
| MENEST ORAL TABLET 0.3 MG, 0.625 MG,      |     | NORDITROPIN FLEXPRO.....                        | 101      |
| 1.25 MG.....                              | 83  | <i>norethindrone-eth estradiol</i> .....        | 83       |
| MENOSTAR.....                             | 83  | NORPACE.....                                    | 71       |
| <i>meprobamate</i> .....                  | 71  | NORPACE CR.....                                 | 71       |
| <i>mesna</i> .....                        | 114 | NORTHERA.....                                   | 169      |
| MESNEX INTRAVENOUS.....                   | 114 | <i>novarel</i> .....                            | 46       |
| <i>metaxall</i> .....                     | 218 | NUCALA.....                                     | 170      |
| <i>metaxalone</i> .....                   | 218 | NUDEXTA.....                                    | 192      |
| <i>methamphetamine hcl</i> .....          | 151 | NULOJIX.....                                    | 172      |
| <i>methitest</i> .....                    | 153 | NUPLAZID ORAL CAPSULE.....                      | 173      |
| <i>methocarbamol oral</i> .....           | 218 | NUPLAZID ORAL TABLET 10 MG, 17 MG...            | 173      |
| <i>methyl dopa oral</i> .....             | 71  | NUTROPIN AQ NUSPIN 10.....                      | 101      |
| <i>methyltestosterone oral</i> .....      | 153 | NUTROPIN AQ NUSPIN 20.....                      | 101      |
| <i>miglustat</i> .....                    | 273 | NUTROPIN AQ NUSPIN 5.....                       | 101      |
| <i>mimvey</i> .....                       | 83  | NYMALIZE ORAL SOLUTION 30 MG/10ML.              | 174      |



|   |     |  |         |
|---|-----|--|---------|
| OICALIVA.....                                       | 175 | <i>phenobarbital oral tablet</i> .....               | 71      |
| <i>octagam intravenous solution 1 gm/20ml</i> ..... | 111 | <i>phrenilin forte oral capsule 50-300-40 mg</i> ... | 36      |
| OCTAGAM INTRAVENOUS SOLUTION 10                     |     | POMALYST .....                                       | 189     |
| GM/100ML, 10 GM/200ML, 2 GM/20ML,                   |     | POTELIGEO .....                                      | 190     |
| 2.5 GM/50ML, 20 GM/200ML, 25                        |     | PRALUENT SUBCUTANEOUS SOLUTION                       |         |
| GM/500ML, 5 GM/100ML, 5 GM/50ML....                 | 111 | PEN-INJECTOR.....                                    | 187     |
| <i>octreotide acetate injection solution 100</i>    |     | PREFEST .....  | 71      |
| <i>mcg/ml, 1000 mcg/ml, 200 mcg/ml, 50</i>          |     | <i>pregnyl</i> .....                                 | 46      |
| <i>mcg/ml, 500 mcg/ml</i> .....                     | 212 | PREMARIN ORAL.....                                   | 83      |
| ODOMZO .....  | 176 | PREMPHASE.....                                       | 83      |
| OFEV .....  | 82  | PREMPRO .....  | 83      |
| OMNITROPE .....                                     | 101 | PREVYMIS ORAL.....                                   | 191     |
| ONCASPAR INJECTION .....                            | 114 | PRIVIGEN .....                                       | 111     |
| OPDIVO INTRAVENOUS SOLUTION 100                     |     | PROCRT .....   | 81, 193 |
| MG/10ML, 40 MG/4ML.....                             | 177 | PROCYSBI.....  | 194     |
| OPSUMIT .....                                       | 178 | PROLASTIN-C INTRAVENOUS SOLUTION                     |         |
| ORALAIR.....  | 179 | RECONSTITUTED 1000 MG .....                          | 198     |
| ORBACTIV .....                                      | 180 | PROLEUKIN .....                                      | 114     |
| ORENITRAM ORAL TABLET EXTENDED                      |     | PROLIA.....  | 62      |
| RELEASE 0.125 MG, 0.25 MG, 1 MG, 2.5                |     | PROMACTA.....  | 195     |
| MG, 5 MG.....                                       | 181 | <i>promethazine hcl injection</i> .....              | 211     |
| ORFADIN.....  | 182 | <i>promethazine hcl oral syrup</i> .....             | 211     |
| ORLISSA ORAL TABLET 150 MG, 200 MG..                | 183 | <i>promethazine hcl oral tablet</i> .....            | 211     |
| ORKAMBI ORAL TABLET .....                           | 184 | <i>promethazine hcl rectal</i> .....                 | 211     |
| OSMOLEX ER.....                                     | 99  | <i>promethazine vc plain oral solution</i> .....     | 196     |
| OTREXUP SUBCUTANEOUS SOLUTION                       |     | <i>promethazine-phenylephrine</i> .....              | 196     |
| AUTO-INJECTOR 10 MG/0.4ML, 12.5                     |     | <i>promethegan rectal suppository 25 mg</i> .....    | 211     |
| MG/0.4ML, 15 MG/0.4ML, 17.5                         |     | PROMETHEGAN RECTAL SUPPOSITORY 50                    |         |
| MG/0.4ML, 20 MG/0.4ML, 22.5                         |     | MG .....   | 211     |
| MG/0.4ML, 25 MG/0.4ML.....                          | 185 | PROVIGIL.....  | 197     |
| <i>oxaliplatin</i> .....                            | 114 | RADICAVA.....  | 199     |
| <i>paclitaxel intravenous concentrate 100</i>       |     | RAGWITEK.....  | 200     |
| <i>mg/16.7ml, 300 mg/50ml</i> .....                 | 114 | RASUVO SUBCUTANEOUS SOLUTION                         |         |
| PALYNZIQ.....                                       | 186 | AUTO-INJECTOR 10 MG/0.2ML, 12.5                      |         |
| <i>pamidronate disodium intravenous</i>             |     | MG/0.25ML, 15 MG/0.3ML, 17.5                         |         |
| <i>solution</i> .....                               | 28  | MG/0.35ML, 20 MG/0.4ML, 22.5                         |         |
| PEGASYS PROCLICK.....                               | 188 | MG/0.45ML, 25 MG/0.5ML, 30 MG/0.6ML,                 |         |
| PEGASYS SUBCUTANEOUS SOLUTION .....                 | 188 | 7.5 MG/0.15ML.....                                   | 201     |
| PEGINTRON SUBCUTANEOUS KIT 50                       |     | RAVICTI.....   | 202     |
| MCG/0.5ML.....                                      | 188 | REBETOL.....   | 188     |
| <i>perphenazine-amitriptyline</i> .....             | 246 | RECLAST .....  | 28      |
| <i>phenadoz rectal suppository 12.5 mg</i> .....    | 71  | REMODULIN .....                                      | 203     |
| PHENERGAN INJECTION.....                            | 71  | REPATHA.....   | 187     |
| <i>phenobarbital oral elixir</i> .....              | 71  | REPATHA PUSHTRONEX SYSTEM.....                       | 187     |

|  |     |  |     |
|--|-----|--|-----|
| REPATHA SURECLICK.....   | 187 | SUTENT.....  | 227 |
| RETACRIT.....  | 81  | SYLATRON SUBCUTANEOUS KIT 200 MCG,<br>300 MCG, 600 MCG.....  | 192 |
| REVATIO.....   | 204 | SYMDEKO.....   | 228 |
| REVLIMID.....  | 205 | SYMLINPEN 120 SUBCUTANEOUS<br>SOLUTION PEN-INJECTOR.....   | 229 |
| RIBASPHERE.....  | 188 | SYMLINPEN 60 SUBCUTANEOUS SOLUTION<br>PEN-INJECTOR.....  | 229 |
| RIBASPHERE RIBAPAK ORAL TABLET 400<br>MG, 600 MG.....                                    | 188 | SYMPROIC.....  | 230 |
| RIBASPHERE RIBAPAK ORAL TABLET<br>THERAPY PACK.....                                      | 188 | SYNAGIS.....   | 231 |
| <i>ribavirin oral capsule</i> .....  | 188 | SYNAREL.....   | 233 |
| <i>ribavirin oral tablet 200 mg</i> .....  | 188 | SYNRIBO.....   | 114 |
| RITUXAN INTRAVENOUS SOLUTION.....  | 206 | TACLONEX EXTERNAL OINTMENT.....  | 192 |
| RUBRACA.....   | 208 | <i>tadalafil (pah)</i> .....   | 5   |
| RUCONEST.....  | 209 | TAFINLAR.....  | 235 |
| RYDAPT.....  | 154 | TAGRISSO.....  | 236 |
| SAIZEN.....  | 101 | TAKHZYRO.....  | 237 |
| SAIZEN CLICK.EASY.....   | 101 | TALWIN.....  | 71  |
| SAIZENPREP.....  | 101 | TAVALISSE.....   | 238 |
| SAMSCA.....  | 210 | TAXOTERE INTRAVENOUS CONCENTRATE<br>80 MG/4ML.....   | 114 |
| SANDOSTATIN INJECTION SOLUTION 100<br>MCG/ML, 1000 MCG/ML, 50 MCG/ML,<br>500 MCG/ML..... | 212 | <i>tazarotene external</i> .....   | 192 |
| SANDOSTATIN LAR DEPOT.....   | 212 | TAZORAC.....   | 192 |
| SEROSTIM SUBCUTANEOUS SOLUTION<br>RECONSTITUTED 4 MG, 5 MG, 6 MG.....                    | 213 | TECENTRIQ.....   | 239 |
| SIGNIFOR.....  | 214 | <i>temsirolimus</i> .....  | 114 |
| <i>sildenafil citrate intravenous</i> .....  | 204 | TENCON ORAL TABLET 50-325 MG.....  | 36  |
| <i>sildenafil citrate oral tablet 20 mg</i> .....  | 204 | TESTIM.....  | 241 |
| SIRTURO.....   | 216 | <i>testosterone cypionate intramuscular<br/>solution 100 mg/ml, 200 mg/ml</i> .....  | 117 |
| SIVEXTRO.....  | 217 | <i>testosterone enanthate intramuscular<br/>solution</i> .....   | 117 |
| SKELAXIN.....  | 218 | <i>testosterone transdermal gel 10 mg/act<br/>(2%), 12.5 mg/act (1%), 20.25 mg/1.25gm<br/>(1.62%), 20.25 mg/act (1.62%), 25<br/>mg/2.5gm (1%), 40.5 mg/2.5gm (1.62%),<br/>50 mg/5gm (1%)</i> ..... | 241 |
| SOMATULINE DEPOT SUBCUTANEOUS<br>SOLUTION 120 MG/0.5ML, 60 MG/0.2ML,<br>90 MG/0.3ML..... | 220 | <i>testosterone transdermal solution</i> .....   | 241 |
| SOMAVERT.....  | 221 | TESTRED.....   | 153 |
| SOVALDI.....   | 222 | <i>tetrabenazine</i> .....   | 265 |
| SPORANOX ORAL SOLUTION.....  | 19  | <i>thioridazine hcl oral</i> .....   | 71  |
| SPRIX.....   | 71  | TIBSOVO.....   | 242 |
| SPRYCEL.....   | 223 | TIGAN ORAL.....  | 243 |
| STIVARGA.....  | 224 | TOBI PODHALER.....   | 244 |
| STRENSIQ.....  | 225 | TORISEL.....   | 114 |
| STRIANT.....   | 241 |  |     |
| SUBSYS.....  | 89  |  |     |
| SUCRAID.....   | 226 |  |     |

|  |     |  |     |
|--|-----|--|-----|
| TRACLEER.....  | 245 | XOLAIR.....  | 267 |
| TREANDA INTRAVENOUS SOLUTION<br>RECONSTITUTED.....                         | 114 | XTANDI.....  | 269 |
| TRELSTAR MIXJECT.....  | 114 | XURIDEN.....   | 270 |
| <i>trientine hcl</i> .....   | 234 | XYREM.....   | 192 |
| <i>trihexyphenidyl hcl</i> .....   | 71  | YERVOY INTRAVENOUS SOLUTION 50<br>MG/10ML.....             | 114 |
| <i>trimethobenzamide hcl oral</i> .....                                    | 243 | YONDELIS.....  | 271 |
| <i>trimipramine maleate oral</i> .....                                     | 246 | ZANOSAR.....   | 114 |
| TRISENOX INTRAVENOUS SOLUTION 12<br>MG/6ML.....                            | 114 | ZAVESCA.....   | 273 |
| TYKERB.....  | 248 | ZEBUTAL ORAL CAPSULE 50-325-40 MG.....                     | 36  |
| TYMLOS.....  | 1   | ZEJULA.....  | 274 |
| TYSABRI.....   | 249 | ZELBORAF.....  | 275 |
| UPTRAVI.....   | 251 | ZEMAIRA.....   | 198 |
| VABOMERE.....  | 192 | ZERBAXA.....   | 276 |
| VALCHLOR.....  | 192 | <i>zileuton er</i> .....                                   | 284 |
| VANATOL LQ.....  | 36  | ZINBRYTA.....  | 278 |
| VECAMYL.....   | 253 | ZINECARD INTRAVENOUS SOLUTION<br>RECONSTITUTED 250 MG..... | 114 |
| VELCADE INJECTION.....   | 114 | ZOCOR ORAL TABLET 80 MG.....                               | 215 |
| VEMLIDY.....   | 254 | <i>zoledronic acid intravenous concentrate</i> .....       | 28  |
| VENCLEXTA.....   | 255 | <i>zoledronic acid intravenous solution</i> .....          | 28  |
| VENCLEXTA STARTING PACK.....   | 255 | <i>zolpidem tartrate er</i> .....                          | 280 |
| VENTAVIS.....  | 256 | <i>zolpidem tartrate oral</i> .....                        | 280 |
| VERZENIO.....  | 257 | ZOMACTON.....  | 101 |
| VIBERZI.....   | 259 | ZOMETA.....  | 28  |
| VIDAZA.....  | 114 | ZONTIVITY.....   | 281 |
| <i>vinblastine sulfate intravenous solution</i> .....                      | 114 | ZORBTIVE.....  | 282 |
| <i>vincasar pfs</i> .....  | 114 | ZURAMPIC.....  | 283 |
| <i>vincristine sulfate intravenous</i> .....                               | 114 | ZYFLO.....   | 284 |
| <i>vinorelbine tartrate intravenous solution</i><br><i>50 mg/5ml</i> ..... | 114 | ZYKADIA.....   | 285 |
| VIVELLE-DOT.....   | 83  | ZYTIGA.....  | 286 |
| <i>voriconazole intravenous</i> .....                                      | 258 | ZYVOX ORAL.....  | 287 |
| <i>voriconazole oral</i> .....   | 258 |  |     |
| VOSEVI.....  | 260 |  |     |
| VOTRIENT.....  | 261 |  |     |
| VPRIV.....   | 262 |  |     |
| VRAYLAR.....   | 263 |  |     |
| VYXEOS.....  | 114 |  |     |
| XALKORI.....   | 264 |  |     |
| XATMEP.....  | 152 |  |     |
| XEOMIN.....  | 33  |  |     |
| XERMELO.....   | 266 |  |     |
| XGEVA.....   | 62  |  |     |